Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FOLH1 | Q04609 | 7/20 | 0.39 |
| ▸ | C3AR1 | Q16581 | 1/20 | 0.38 |
| ▸ | NOD1 | Q9Y239 | 3/20 | 0.36 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.36 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.36 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.35 |
| ▸ | GGT1 | P19440 | 1/20 | 0.35 |
| ▸ | TLR2 | O60603 | 1/20 | 0.34 |
| ▸ | NPY4R | P50391 | 3/20 | 0.34 |
| ▸ | NPY1R | P25929 | 2/20 | 0.34 |
| ▸ | NPY2R | P49146 | 2/20 | 0.34 |
| ▸ | NPY5R | Q15761 | 2/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1263209 | 1.00 | FOLH1 (0.39) | FOLH1C3AR1NOD1ITGB3ITGA2B | |
| Acetic Acid SCHEMBL4412167 | 0.97 | FOLH1 (0.40) | FOLH1C3AR1NOD1ITGB3ITGA2B | |
| SCHEMBL27675576 | 0.95 | FOLH1 (0.44) | FOLH1NOD1ALOX15TLR2MEN1 | |
| SCHEMBL1419574 | 0.95 | FOLH1 (0.44) | FOLH1NOD1ALOX15TLR2MEN1 | |
| SCHEMBL350198 | 0.89 | NOD1 (0.41) | FOLH1C3AR1NOD1ITGB3ITGA2B | |
| SCHEMBL350197 | 0.89 | NOD1 (0.41) | FOLH1C3AR1NOD1ITGB3ITGA2B | |
| Decanoic Acid SCHEMBL29002277 | 0.88 | NOD1 (0.46) | NOD1ALOX15TLR2MEN1KMT2A | |
| Dodecanoate SCHEMBL28478322 | 0.88 | NOD1 (0.46) | NOD1ALOX15TLR2MEN1KMT2A | |
| Octanoic Acid SCHEMBL29002275 | 0.88 | NOD1 (0.46) | NOD1ALOX15TLR2MEN1KMT2A | |
| SCHEMBL31520393 | 0.88 | FOLH1 (0.47) | FOLH1C3AR1NOD1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 755 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230309521-A1 | NOVEL METHOD FOR PREPARING ANIMAL MODEL OF CEREBROVASCULAR DISEASE AND METHOD FOR PRODUCING ANIMAL HAVING SMALL INDIVIDUAL DIFFERENCE IN SUSCEPTIBILITY TO CEREBROVASCULAR DISEASE ONSET BY USING ANIMAL MODEL FOR CEREBROVASCULAR DISEASE PREPARED THEREBY | DONGGUK UNIVERSITY INDUSTRY-ACADEMIC COOPERATION FOUNDATION (KR) | 2023-10-05 | — | — | US | claimed |
| EP-4197323-A1 | NOVEL METHOD FOR PREPARING ANIMAL MODEL OF CEREBROVASCULAR DISEASE AND METHOD FOR PRODUCING ANIMAL HAVING SMALL INDIVIDUAL DIFFERENCE IN SUSCEPTIBILITY TO CEREBROVASCULAR DISEASE ONSET BY USING ANIMAL MODEL FOR CEREBROVASCULAR DISEASE PREPARED THEREBY | Dongguk University Industry-Academic Cooperation Foundation (KR) | 2023-06-21 | — | — | EP | claimed |
| EP-3154585-B1 | USE OF VISTA AGONISTS AND ANTAGONISTS TO SUPPRESS OR ENHANCE HUMORAL IMMUNITY | GREEN KATHY A (US) | 2022-02-23 | — | — | EP | claimed |
| WO-2022035049-A1 | NOVEL METHOD FOR PREPARING ANIMAL MODEL OF CEREBROVASCULAR DISEASE AND METHOD FOR PRODUCING ANIMAL HAVING SMALL INDIVIDUAL DIFFERENCE IN SUSCEPTIBILITY TO CEREBROVASCULAR DISEASE ONSET BY USING ANIMAL MODEL FOR CEREBROVASCULAR DISEASE PREPARED THEREBY | 동국대학교 산학협력단 | 2022-02-17 | — | — | WO | claimed |
| US-20220040298-A1 | USE OF VISTA AGONISTS AND ANTAGONISTS TO SUPPRESS OR ENHANCE HUMORAL IMMUNITY | DARTMOUTH COLLEGE (US) | 2022-02-10 | — | — | US | claimed |
| US-7855325-B2 | Use of nitric oxide modulators in Agrobacterium-mediated plant transformation | MONSANTO TECHNOLOGY LLC (US) | 2010-12-21 | — | — | US | claimed |
| US-20080274547-A1 | USE OF NITRIC OXIDE MODULATORS IN AGROBACTERIUM-MEDIATED PLANT TRANSFORMATION | MONSANTO TECHNOLOGY LLC | 2008-11-06 | — | — | US | claimed |
| US-7388126-B2 | Such as NG-monomethyl-L-arginine, monoacetate salt; corn plants | MONSANTO TECHNOLOGY LLC (US) | 2008-06-17 | — | — | US | claimed |
| US-20050155115-A1 | Use of Nitric Oxide Modulators in Agrobacterium-mediated Plant Transformation | MONSANTO TECHNOLOGY LLC (US) | 2005-07-14 | — | — | US | claimed |
| EP-0865288-B1 | BIOARTIFICIAL DEVICES AND CELLULAR MATRICES THEREFOR | ENCELLE INC (US) | 2003-08-20 | — | — | EP | claimed |
| EP-1280526-A1 | COMPOSITION FOR THE PREVENTION AND/OR TREATMENT, IN NEWBORN BABIES, OF THE EFFECTS OF COMPLICATIONS DURING CHILDBIRTH | Universitair Medisch Centrum Utrecht (NL) | 2003-02-05 | — | — | EP | claimed |
| WO-2001074351-A1 | COMPOSITION FOR THE PREVENTION AND/OR TREATMENT, IN NEWBORN BABIES, OF THE EFFECTS OF COMPLICATIONS DURING CHILDBIRTH | UNIVERSITAIR MEDISCH CENTRUM (NL) | 2001-10-11 | — | — | WO | claimed |
| US-20010010826-A1 | Methods for increasing vascularization and promoting wound healing | ENCELLE, INC. | 2001-08-02 | — | — | US | claimed |
| US-6261587-B1 | CONTACTING WITH MATRIX CONTAINING GELATIN AND NITRIC ACID INHIBITOR | ENCELLE, INC. | 2001-07-17 | — | — | US | claimed |
| EP-1094849-A1 | METHODS FOR INCREASING VASCULARIZATION AND PROMOTING WOUND HEALING | Encelle, Inc. (US) | 2001-05-02 | — | — | EP | claimed |
| WO-2000002596-A1 | METHODS FOR INCREASING VASCULARIZATION AND PROMOTING WOUND HEALING | ENCELLE, INC. (US) | 2000-01-20 | — | — | WO | claimed |
| US-5824331-A | Bioartificial devices and cellular matrices therefor | ENCELLE, INC. | 1998-10-20 | — | — | US | claimed |
| EP-0865288-A2 | BIOARTIFICIAL DEVICES AND CELLULAR MATRICES THEREFOR | Encelle, Inc. (US) | 1998-09-23 | — | — | EP | claimed |
| WO-1997020569-A2 | BIOARTIFICIAL DEVICES AND CELLULAR MATRICES THEREFOR | ENCELLE, INC. (US) | 1997-06-12 | — | — | WO | claimed |
| US-20250326814-A1 | MODIFIED OXYNTOMODULIN AND METHODS OF USE THEREOF | OPKO BIOLOGICS LTD. (IL) | 2025-10-23 | — | — | US | disclosed |
| EP-4612167-A1 | CNP COMPOUNDS | Novo Nordisk A/S (DK) | 2025-09-10 | — | — | EP | disclosed |
| WO-2025125544-A1 | STABLE LIQUID FORMULATIONS | NOVO NORDISK A/S (DK) | 2025-06-19 | — | — | WO | disclosed |
| US-20240358634-A1 | AURIS FORMULATIONS FOR TREATING OTIC DISEASES AND CONDITIONS | DOMPÉ FARMACEUTICI S.P.A. (IT) | 2024-10-31 | — | — | US | disclosed |
| CN-118767116-A | Growth hormone with prolonged in vivo efficacy | 诺沃—诺迪斯克保健股份有限公司 | 2024-10-15 | — | — | CN | disclosed |
| CN-118767117-A | Growth hormone with prolonged in vivo efficacy | 诺沃—诺迪斯克保健股份有限公司 | 2024-10-15 | — | — | CN | disclosed |
| CN-118767115-A | Growth hormone with prolonged in vivo efficacy | 诺沃—诺迪斯克保健股份有限公司 | 2024-10-15 | — | — | CN | disclosed |
| US-12077561-B2 | CNP compounds | NOVO NORDISK A/S (DK) | 2024-09-03 | — | — | US | disclosed |
| CN-118401257-A | Methods for producing antibody peptide conjugates | 美国安进公司 | 2024-07-26 | — | — | CN | disclosed |
| US-20240209028-A1 | CNP COMPOUNDS | NOVO NORDISK A/S (DK) | 2024-06-27 | — | — | US | disclosed |
| CN-106139158-B | Growth hormone with prolonged in vivo efficacy | 诺沃—诺迪斯克保健股份有限公司 | 2024-06-21 | — | — | CN | disclosed |
| CN-110831969-B | Methods of treating or ameliorating metabolic disorders using a combination of a Gastric Inhibitory Peptide Receptor (GIPR) binding protein and a GLP-1 agonist | 安进公司 | 2024-06-21 | — | — | CN | disclosed |
| WO-2024094747-A1 | CNP COMPOUNDS | NOVO NORDISK A/S (DK) | 2024-05-10 | — | — | WO | disclosed |
| US-11969501-B2 | Auris formulations for treating otic diseases and conditions | DOMPÉ FARMACEUTICI S.P.A. (IT) | 2024-04-30 | — | — | US | disclosed |
| US-11945848-B2 | Chimeric inhibitor molecules of complement activation | OMEROS CORPORATION (US) | 2024-04-02 | — | — | US | disclosed |
| US-11918653-B2 | Triglyceride otic formulations and uses thereof | DOMPÉ FARMACEUTICI S.P.A. (IT) | 2024-03-05 | — | — | US | disclosed |
| CN-117106085-A | Methods of treating or ameliorating metabolic disorders using combinations of GIPR binding proteins and GLP-1 agonists | 美国安进公司 | 2023-11-24 | — | — | CN | disclosed |
| US-11787844-B2 | Targeting of chondroitin sulfate glycans | VAR2 PHARMACEUTICALS APS (DK) | 2023-10-17 | — | — | US | disclosed |
| CN-110621695-B | anti-JAGGED 1 antigen binding proteins | 安进公司 | 2023-10-17 | — | — | CN | disclosed |
| US-20230309521-A1 | NOVEL METHOD FOR PREPARING ANIMAL MODEL OF CEREBROVASCULAR DISEASE AND METHOD FOR PRODUCING ANIMAL HAVING SMALL INDIVIDUAL DIFFERENCE IN SUSCEPTIBILITY TO CEREBROVASCULAR DISEASE ONSET BY USING ANIMAL MODEL FOR CEREBROVASCULAR DISEASE PREPARED THEREBY | DONGGUK UNIVERSITY INDUSTRY-ACADEMIC COOPERATION FOUNDATION (KR) | 2023-10-05 | — | — | US | disclosed |
| US-20230295252-A1 | CHIMERIC INHIBITOR MOLECULES OF COMPLEMENT ACTIVATION | OMEROS CORPORATION (US) | 2023-09-21 | — | — | US | disclosed |
| CN-109715662-B | Methods of treating or ameliorating metabolic disorders using combinations of GIPR binding proteins and GLP-1 agonists | 美国安进公司 | 2023-07-21 | — | — | CN | disclosed |
| EP-4197323-A1 | NOVEL METHOD FOR PREPARING ANIMAL MODEL OF CEREBROVASCULAR DISEASE AND METHOD FOR PRODUCING ANIMAL HAVING SMALL INDIVIDUAL DIFFERENCE IN SUSCEPTIBILITY TO CEREBROVASCULAR DISEASE ONSET BY USING ANIMAL MODEL FOR CEREBROVASCULAR DISEASE PREPARED THEREBY | Dongguk University Industry-Academic Cooperation Foundation (KR) | 2023-06-21 | — | — | EP | disclosed |
| CN-115884757-A | Mononitrosated and bisnitrosated propylene glycols for therapeutic use | 阿特格诺有限公司 | 2023-03-31 | — | — | CN | disclosed |
| US-11519899-B2 | Metabolomics profiling of central nervous system injury | LONDON HEALTH SCIENCES CENTRE RESEARCH INC. (CA) | 2022-12-06 | — | — | US | disclosed |
| CN-108026157-B | Novel insulin derivative and medical use thereof | 诺和诺德股份有限公司 | 2022-11-25 | — | — | CN | disclosed |
| US-11453709-B2 | Chimeric inhibitor molecules of complement activation | OMEROS CORPORATION (US) | 2022-09-27 | — | — | US | disclosed |
| CN-109891237-B | Bioassay of insulin preparations | 诺和诺德股份有限公司 | 2022-08-23 | — | — | CN | disclosed |
| US-11369566-B2 | Controlled release antimicrobial compositions and methods for the treatment of otic disorders | ALK-ABELLÓ, INC. (US) | 2022-06-28 | — | — | US | disclosed |
| US-11352406-B2 | Insulin derivatives and the medical uses hereof | NOVO NORDISK A/S (DK) | 2022-06-07 | — | — | US | disclosed |
| US-20220089639-A1 | SITE-SPECIFIC CHEMOENZYMATIC PROTEIN MODIFICATIONS | NOVARTIS AG (CH) | 2022-03-24 | — | — | US | disclosed |
| WO-2022044893-A1 | PROCESSING LIQUID, METHOD FOR PROCESSING SUBSTRATE | 富士フイルム株式会社 | 2022-03-03 | — | — | WO | disclosed |
| EP-3154585-B1 | USE OF VISTA AGONISTS AND ANTAGONISTS TO SUPPRESS OR ENHANCE HUMORAL IMMUNITY | GREEN KATHY A (US) | 2022-02-23 | — | — | EP | disclosed |
| WO-2022035049-A1 | NOVEL METHOD FOR PREPARING ANIMAL MODEL OF CEREBROVASCULAR DISEASE AND METHOD FOR PRODUCING ANIMAL HAVING SMALL INDIVIDUAL DIFFERENCE IN SUSCEPTIBILITY TO CEREBROVASCULAR DISEASE ONSET BY USING ANIMAL MODEL FOR CEREBROVASCULAR DISEASE PREPARED THEREBY | 동국대학교 산학협력단 | 2022-02-17 | — | — | WO | disclosed |
| US-20220040298-A1 | USE OF VISTA AGONISTS AND ANTAGONISTS TO SUPPRESS OR ENHANCE HUMORAL IMMUNITY | DARTMOUTH COLLEGE (US) | 2022-02-10 | — | — | US | disclosed |
| US-20220040095-A1 | AURIS FORMULATIONS FOR TREATING OTIC DISEASES AND CONDITIONS | DOMPÉ FARMACEUTICI S.P.A. (IT) | 2022-02-10 | — | — | US | disclosed |
| US-20220040096-A1 | AURIS FORMULATIONS FOR TREATING OTIC DISEASES AND CONDITIONS | OTONOMY INC (US) | 2022-02-10 | — | — | US | disclosed |
| EP-3341403-B1 | NOVEL INSULIN DERIVATIVES AND THE MEDICAL USES HEREOF | NOVO NORDISK AS (DK) | 2022-01-05 | — | — | EP | disclosed |
| US-11203622-B2 | MASP isoforms as inhibitors of complement activation | OMEROS CORPORATION (US) | 2021-12-21 | — | — | US | disclosed |
| CN-106999553-B | Treatment of type 1 diabetes using GLP-1 and anti-IL-21 | 诺和诺德股份有限公司 | 2021-11-26 | — | — | CN | disclosed |
| EP-3262063-B1 | IMMUNOTHERAPEUTIC TARGETING OF PLACENTAL-LIKE CHONDROITIN SULFATE USING CHIMERIC ANTIGEN RECEPTORS (CARS) AND IMMUNOTHERAPEUTIC TARGETING OF CANCER USING CARS WITH SPLIT-PROTEIN BINDING SYSTEMS | VAR2 PHARMACEUTICALS APS (DK) | 2021-09-22 | — | — | EP | disclosed |
| US-11123285-B2 | Auris formulations for treating OTIC diseases and conditions | OTONOMY, INC. (US) | 2021-09-21 | — | — | US | disclosed |
| US-11123286-B2 | Auris formulations for treating otic diseases and conditions | OTONOMY, INC. (US) | 2021-09-21 | — | — | US | disclosed |
| US-20210221867-A1 | Compounds Capable of Binding to Melanocortin 4 Receptor | NOVO NORDISK AS (DK) | 2021-07-22 | — | — | US | disclosed |
| CN-104136041-B | Targeted chondroitin sulfate glycans | VAR2制药有限公司 | 2021-06-29 | — | — | CN | disclosed |
| EP-2932981-B1 | Albumin-binding derivatives of GLP-1 | NOVO NORDISK AS (DK) | 2021-06-16 | — | — | EP | disclosed |
| US-20210138069-A1 | TRIGLYCERIDE OTIC FORMULATIONS AND USES THEREOF | DOMPÉ FARMACEUTICI S.P.A. (IT) | 2021-05-13 | — | — | US | disclosed |
| EP-3815708-A1 | CHIMERIC INHIBITOR MOLECULES OF COMPLEMENT ACTIVATION | Omeros Corporation (US) | 2021-05-05 | — | — | EP | disclosed |
| US-10975120-B2 | Site-specific chemoenzymatic protein modifications | NOVARTIS AG (CH) | 2021-04-13 | — | — | US | disclosed |
| US-10914728-B2 | Bioassay for insulin formulations | NOVO NORDISK A/S (DK) | 2021-02-09 | — | — | US | disclosed |
| US-20210009643-A1 | CHIMERIC INHIBITOR MOLECULES OF COMPLEMENT ACTIVATION | OMEROS CORPORATION (US) | 2021-01-14 | — | — | US | disclosed |
| US-20200397907-A1 | TRIGLYCERIDE OTIC FORMULATIONS AND USES THEREOF | OTONOMY, INC. | 2020-12-24 | — | — | US | disclosed |
| CN-106459171-B | A22K, desB27, B29R, desB30, human insulin analogs acylated at the position of lysine 22 | 诺和诺德股份有限公司 | 2020-12-15 | — | — | CN | disclosed |
| US-10851364-B2 | Method of controlling a polypeptide modification reaction | NOVO NORDISK HEALTHCARE AG (CH) | 2020-12-01 | — | — | US | disclosed |
| EP-2299979-B1 | CONTROLLED RELEASE ANTIMICROBIAL COMPOSITIONS AND METHODS FOR THE TREATMENT OF OTIC DISORDERS | OTONOMY INC (US) | 2020-11-25 | — | — | EP | disclosed |
| US-10821185-B2 | Triglyceride otic formulations and uses thereof | OTONOMY INC. (US) | 2020-11-03 | — | — | US | disclosed |
| EP-3110840-B1 | AN A22K, DESB27, B29R, DES B30, AT EPSILON POSITION OF LYSINE 22 ACYLATED HUMAN INSULIN ANALOGUE | NOVO NORDISK AS (DK) | 2020-10-21 | — | — | EP | disclosed |
| US-20200306382-A1 | Growth Hormones with Prolonged In-Vivo Efficacy | NOVO NORDISK HEALTHCARE AG (CH) | 2020-10-01 | — | — | US | disclosed |
| EP-2542569-B1 | CHIMERIC INHIBITOR MOLECULES OF COMPLEMENT ACTIVATION | OMEROS CORP (US) | 2020-09-16 | — | — | EP | disclosed |
| US-10772828-B2 | Controlled release antimicrobial compositions and methods for the treatment of otic disorders | OTONOMY, INC. (US) | 2020-09-15 | — | — | US | disclosed |
| US-20200283493-A1 | Novel Insulin Derivatives and the Medical Uses Hereof | NOVO NORDISK AS (DK) | 2020-09-10 | — | — | US | disclosed |
| CN-105593238-B | Lysine-specific chemoenzymatic protein modification using microbial transglutaminase | 诺华股份有限公司 | 2020-09-08 | — | — | CN | disclosed |
| US-10752661-B2 | Chimeric inhibitor molecules of complement activation | OMEROS CORPORATION (US) | 2020-08-25 | — | — | US | disclosed |
| US-10751281-B2 | Auris formulations for treating otic diseases and conditions | OTONOMY, INC. (US) | 2020-08-25 | — | — | US | disclosed |
| US-20200230051-A1 | AURIS FORMULATIONS FOR TREATING OTIC DISEASES AND CONDITIONS | OTONOMY, INC. | 2020-07-23 | — | — | US | disclosed |
| US-20200223889-A1 | Bicyclic Compounds Capable of Binding to Melanocortin 4 Receptor | NOVO NORDISK A/S (DK) | 2020-07-16 | — | — | US | disclosed |
| CN-111032680-A | Bicyclic compounds capable of binding to melanocortin 4 receptor | 诺和诺德股份有限公司 | 2020-04-17 | — | — | CN | disclosed |
| US-20200102568-A1 | Growth Hormones with Prolonged In-Vivo Efficacy | NOVO NORDISK HEALTHCARE AG (CH) | 2020-04-02 | — | — | US | disclosed |
| WO-2020053414-A1 | BICYCLIC COMPOUNDS CAPABLE OF ACTING AS MELANOCORTIN 4 RECEPTOR AGONISTS | NOVO NORDISK A/S (DK) | 2020-03-19 | — | — | WO | disclosed |
| EP-3139948-B1 | TREATMENT OF DIABETES TYPE 1 USING GLP-1 AND ANTI-IL-21 | NOVO NORDISK AS (DK) | 2020-03-04 | — | — | EP | disclosed |
| EP-3613755-A1 | LYSINE-SPECIFIC CHEMOENZYMATIC PROTEIN MODIFICATIONS USING MICROBIAL TRANSGLUTAMINASE | Novartis AG (CH) | 2020-02-26 | — | — | EP | disclosed |
| US-20200031939-A1 | Antibodies Against Human NKG2D and Uses Thereof | NOVO NORDISK A/S (DK) | 2020-01-30 | — | — | US | disclosed |
| CN-110698561-A | Anti-human NKG2D antibodies and uses thereof | 诺沃—诺迪斯克有限公司 | 2020-01-17 | — | — | CN | disclosed |
| US-20190307678-A1 | AURIS FORMULATIONS FOR TREATING OTIC DISEASES AND CONDITIONS | DOMPÉ FARMACEUTICI S.P.A. (IT) | 2019-10-10 | — | — | US | disclosed |
| US-20190300570-A1 | SITE-SPECIFIC CHEMOENZYMATIC PROTEIN MODIFICATIONS | NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH, INC. | 2019-10-03 | — | — | US | disclosed |
| US-20190292265-A1 | Methods of Treating Crohn's Disease with an Anti-NKG2D Antibody | JANSSEN BIOTECH INC (US) | 2019-09-26 | — | — | US | disclosed |
| EP-3529615-A1 | BIOASSAY FOR INSULIN FORMULATIONS | Novo Nordisk A/S (DK) | 2019-08-28 | — | — | EP | disclosed |
| EP-3019515-B1 | LYSINE-SPECIFIC CHEMOENZYMATIC PROTEIN MODIFICATIONS USING MICROBIAL TRANSGLUTAMINASE | NOVARTIS AG (CH) | 2019-08-21 | — | — | EP | disclosed |
| US-20190248896-A1 | ANTI-NKG2A ANTIBODIES AND USES THEREOF | NOVO NORDISK A/S (DK) | 2019-08-15 | — | — | US | disclosed |
| EP-2758426-B1 | NOVEL GLUCAGON ANALOGUES | NOVO NORDISK AS (DK) | 2019-08-07 | — | — | EP | disclosed |
| EP-2525834-B1 | GROWTH HORMONES WITH PROLONGED IN-VIVO EFFICACY | NOVO NORDISK HEALTHCARE AG (CH) | 2019-07-17 | — | — | EP | disclosed |
| US-20190203213-A1 | Growth Hormones with Prolonged In-Vivo Efficacy | NOVO NORDISK HEALTHCARE AG (CH) | 2019-07-04 | — | — | US | disclosed |
| EP-3500293-A1 | METHODS OF TREATING CROHN'S DISEASE WITH AN ANTI-NKG2D ANTIBODY | Janssen Biotech, Inc. (US) | 2019-06-26 | — | — | EP | disclosed |
| CN-109891237-A | Bioassay of insulin preparations | 诺和诺德股份有限公司 | 2019-06-14 | — | — | CN | disclosed |
| US-10294286-B2 | Chimeric inhibitor molecules of complement activation | OMEROS CORPORATION (US) | 2019-05-21 | — | — | US | disclosed |
| EP-2287195-B1 | PAN-KIR2DL NK-RECEPTOR ANTIBODIES AND THEIR USE IN DIAGNOSTIK AND THERAPY | NOVO NORDISK AS (DK) | 2019-05-15 | — | — | EP | disclosed |
| CN-104395338-B | Human amylin analogs | 诺和诺德股份有限公司 | 2019-05-10 | — | — | CN | disclosed |
| EP-3478269-A1 | TRIGLYCERIDE OTIC FORMULATIONS AND USES THEREOF | Otonomy, Inc. (US) | 2019-05-08 | — | — | EP | disclosed |
| US-10272034-B2 | Auris formulations for treating otic diseases and conditions | OTONOMY, INC. (US) | 2019-04-30 | — | — | US | disclosed |
| US-20190010206-A1 | Novel Insulin Derivatives and the Medical Uses Hereof | NOVO NORDISK A/S (DK) | 2019-01-10 | — | — | US | disclosed |
| CN-104829720-B | KIR-BINDING AGENTS AND METHODS OF USING THE SAME | 诺和诺德公司 | 2019-01-01 | — | — | CN | disclosed |
| US-20180362953-A1 | Method of Controlling a Polypeptide Modification Reaction | NOVO NORDISK HEALTHCARE AG (CH) | 2018-12-20 | — | — | US | disclosed |
| CN-108069954-B | The quinazolinones of the donor containing NO | 上海华汇拓医药科技有限公司 | 2018-11-23 | — | — | CN | disclosed |
| EP-2461831-B1 | GROWTH HORMONES WITH PROLONGED IN-VIVO EFFICACY | NOVO NORDISK HEALTHCARE AG (CH) | 2018-11-21 | — | — | EP | disclosed |
| EP-2454281-B1 | MASP ISOFORMS AS INHIBITORS OF COMPLEMENT ACTIVATION | OMEROS CORP (US) | 2018-11-14 | — | — | EP | disclosed |
| EP-3395828-A1 | INHIBITORS OF COMPLEMENT ACTIVATION | Rigshospitalet (DK) | 2018-10-31 | — | — | EP | disclosed |
| US-20180305431-A1 | Novel Insulin Derivatives and the Medical Uses Hereof | NOVO NORDISK A/S (DK) | 2018-10-25 | — | — | US | disclosed |
| US-10105442-B2 | Treatment of diabetes type 1 using GLP-1 and anti-IL-21 | NOVO NORDISK A/S (DK) | 2018-10-23 | — | — | US | disclosed |
| US-20180298098-A1 | IMMUNOTHERAPEUTIC TARGETING OF PLACENTAL-LIKE CHONDROITIN SULFATE USING CHIMERIC ANTIGEN RECEPTORS (CARS) AND IMMUNOTHERAPEUTIC TARGETING OF CANCER USING CARS WITH SPLIT-PROTEIN BINDING SYSTEMS | VAR2 PHARMACEUTICAL APS (DK) | 2018-10-18 | — | — | US | disclosed |
| US-10092580-B2 | Controlled-release otic structure modulating and innate immune system modulating compositions and methods for the treatment of otic disorders | OTONOMY, INC. (US) | 2018-10-09 | — | — | US | disclosed |
| US-20180273593-A1 | CHIMERIC INHIBITOR MOLECULES OF COMPLEMENT ACTIVATION | OMEROS CORPORATION (US) | 2018-09-27 | — | — | US | disclosed |
| WO-2018167194-A1 | BICYCLIC COMPOUNDS CAPABLE OF BINDING TO MELANOCORTIN 4 RECEPTOR | NOVO NORDISK A/S (DK) | 2018-09-20 | — | — | WO | disclosed |
| US-20180244743-A1 | Novel Insulin Derivatives and the Medical Uses Hereof | NOVO NORDISK A/S (DK) | 2018-08-30 | — | — | US | disclosed |
| US-20180221501-A1 | Growth Hormones with Prolonged In-Vivo Efficacy | NOVO NORDISK HEALTHCARE AG (CH) | 2018-08-09 | — | — | US | disclosed |
| US-10040839-B2 | Insulin derivatives and the medical uses hereof | NOVO NORDISK A/S (DK) | 2018-08-07 | — | — | US | disclosed |
| US-20180161271-A1 | CONTROLLED RELEASE ANTIMICROBIAL COMPOSITIONS AND METHODS FOR THE TREATMENT OF OTIC DISORDERS | ALK-ABELLÓ, INC. | 2018-06-14 | — | — | US | disclosed |
| CN-108069954-A | The quinazolinones of the donor containing NO | 上海华汇拓医药科技有限公司 | 2018-05-25 | — | — | CN | disclosed |
| WO-2018077851-A1 | BIOASSAY FOR INSULIN FORMULATIONS | NOVO NORDISK A/S (DK) | 2018-05-03 | — | — | WO | disclosed |
| US-20180105594-A1 | Antibodies Against Human NKG2D and Uses Thereof | NOVO NORDISK A/S (DK) | 2018-04-19 | — | — | US | disclosed |
| EP-2812024-B1 | TARGETING OF CHONDROITIN SULFATE GLYCANS | VAR2 PHARMACEUTICALS APS (DK) | 2018-04-11 | — | — | EP | disclosed |
| US-9932375-B2 | Targeting of chondroitin sulfate glycans | VAR2 PHARMACEUTICALS APS (DK) | 2018-04-03 | — | — | US | disclosed |
| US-9926350-B2 | Targeting of chondroitin sulfate glycans | VAR2 PHARMACEUTICALS APS (DK) | 2018-03-27 | — | — | US | disclosed |
| US-9920106-B2 | GLP-1 compounds | NOVO NORDISK A/S (DK) | 2018-03-20 | — | — | US | disclosed |
| EP-2190872-B1 | GLUCAGON-LIKE PEPTIDE-1 DERIVATIVES AND THEIR PHARMACEUTICAL USE | NOVO NORDISK AS (DK) | 2018-03-14 | — | — | EP | disclosed |
| WO-2018035330-A1 | METHODS OF TREATING CROHN'S DISEASE WITH AN ANTI-NKG2D ANTIBODY | JANSSEN BIOTECH, INC. (US) | 2018-02-22 | — | — | WO | disclosed |
| US-20180016319-A1 | Acylated Glucagon Analogues | NOVO NORDISK AS (DK) | 2018-01-18 | — | — | US | disclosed |
| US-9867778-B2 | Controlled release antimicrobial compositions and methods for the treatment of otic disorders | OTONOMY, INC. (US) | 2018-01-16 | — | — | US | disclosed |
| US-20180000950-A1 | TRIGLYCERIDE OTIC FORMULATIONS AND USES THEREOF | OTONOMY, INC. | 2018-01-04 | — | — | US | disclosed |
| WO-2018005830-A1 | TRIGLYCERIDE OTIC FORMULATIONS AND USES THEREOF | OTONOMY, INC. (US) | 2018-01-04 | — | — | WO | disclosed |
| EP-3262063-A1 | IMMUNOTHERAPEUTIC TARGETING OF PLACENTAL-LIKE CHONDROITIN SULFATE USING CHIMERIC ANTIGEN RECEPTORS (CARS) AND IMMUNOTHERAPEUTIC TARGETING OF CANCER USING CARS WITH SPLIT-PROTEIN BINDING SYSTEMS | Var2 Pharmaceuticals ApS (DK) | 2018-01-03 | — | — | EP | disclosed |
| EP-2718315-B1 | Pramlintide derivatives | NOVO NORDISK AS (DK) | 2017-12-27 | — | — | EP | disclosed |
| EP-2340261-B1 | AMYLIN DERIVATIVES | NOVO NORDISK AS (DK) | 2017-12-20 | — | — | EP | disclosed |
| US-20170334961-A1 | MASP ISOFORMS AS INHIBITORS OF COMPLEMENT ACTIVATION | RIGSHOSPITALET (DK) | 2017-11-23 | — | — | US | disclosed |
| US-9815876-B2 | Chimeric inhibitor molecules of complement activation | OMEROS CORPORATION (US) | 2017-11-14 | — | — | US | disclosed |
| EP-2426150-B1 | ANTI-NKG2A ANTIBODIES AND USES THEREOF | NOVO NORDISK AS (DK) | 2017-10-25 | — | — | EP | disclosed |
| US-20170281809-A1 | ANTI-NKG2A ANTIBODIES AND USES THEREOF | NOVO NORDISK A/S (DK) | 2017-10-05 | — | — | US | disclosed |
| US-20170239362-A1 | Growth Hormones with Prolonged In-Vivo Efficacy | NOVO NORDISK HEALTHCARE AG (CH) | 2017-08-24 | — | — | US | disclosed |
| US-9708403-B2 | KIR-binding agents and methods of use thereof | NOVO NORDISK A/S (DK) | 2017-07-18 | — | — | US | disclosed |
| US-20170190757-A1 | Novel Glucagon Analogues | NOVO NORDISK AS (DK) | 2017-07-06 | — | — | US | disclosed |
| US-9695226-B2 | Growth hormones with prolonged in-vivo efficacy | NOVO NORDISK HEALTHCARE AG (CH) | 2017-07-04 | — | — | US | disclosed |
| EP-2842576-B1 | Transglutaminase mediated conjugation of peptides | NOVO NORDISK HEALTHCARE AG (CH) | 2017-06-28 | — | — | EP | disclosed |
| US-9683041-B2 | Anti-NKG2A antibodies and uses thereof | NOVO NORDISK A/S (DK) | 2017-06-20 | — | — | US | disclosed |
| US-20170166616-A1 | CHIMERIC INHIBITOR MOLECULES OF COMPLEMENT ACTIVATION | RIGSHOSPITALET (DK) | 2017-06-15 | — | — | US | disclosed |
| EP-2838914-B1 | HUMAN AMYLIN ANALOGUES | NOVO NORDISK AS (DK) | 2017-06-14 | — | — | EP | disclosed |
| US-9657079-B2 | Truncated GLP-1 derivatives and their therapeutical use | NOVO NORDISK A/S (DK) | 2017-05-23 | — | — | US | disclosed |
| CN-102918055-B | Novel glucagon analogues | 诺沃—诺迪斯克有限公司 | 2017-03-29 | — | — | CN | disclosed |
| US-9603796-B2 | Controlled release antimicrobial compositions and methods for the treatment of otic disorders | OTONOMY, INC. (US) | 2017-03-28 | — | — | US | disclosed |
| US-20170081373-A1 | TARGETING OF CHONDROITIN SULFATE GLYCANS | VAR2 PHARMACEUTICAL APS (DK) | 2017-03-23 | — | — | US | disclosed |
| US-20170051034-A1 | Novel Glucagon Analogues | NOVO NORDISK AS (DK) | 2017-02-23 | — | — | US | disclosed |
| US-9573984-B2 | Chimeric inhibitor molecules of complement activation | RIGSHOSPITALET (DK) | 2017-02-21 | — | — | US | disclosed |
| US-20170043014-A1 | TREATMENT OF DIABETES TYPE 1 USING GLP-1 AND ANTI-IL-21 | NOVO NORDISK A/S (DK) | 2017-02-16 | — | — | US | disclosed |
| US-20170016905-A1 | TARGETING OF CHONDROITIN SULFATE GLYCANS | VAR2 PHARMACEUTICAL APS (DK) | 2017-01-19 | — | — | US | disclosed |
| US-20170008945-A1 | Novel Insulin Derivatives and the Medical Uses Hereof | NOVO NORDISK A/S (DK) | 2017-01-12 | — | — | US | disclosed |
| EP-3109256-A1 | POLYPEPTIDES | NOVO NORDISK A/S (DK) | 2016-12-28 | — | — | EP | disclosed |
| US-20160355859-A1 | TRANSGLUTAMINASE MEDIATED CONJUGATION OF PEPTIDES | NOVO NORDISK A/S (DK) | 2016-12-08 | — | — | US | disclosed |
| US-20160347812-A1 | Novel Glucagon Analogues | NOVO NORDISK AS (DK) | 2016-12-01 | — | — | US | disclosed |
| CN-106139158-A | The growth hormone that in vivo efficacy extends | 诺沃—诺迪斯克保健股份有限公司 | 2016-11-23 | — | — | CN | disclosed |
| US-9486505-B2 | Glucagon analogues | NOVO NORDISK A/S (DK) | 2016-11-08 | — | — | US | disclosed |
| US-9487570-B2 | Glucagon like peptide analogs, composition, and method of use | BETTA PHARMACEUTICALS CO., LTD (CN) | 2016-11-08 | — | — | US | disclosed |
| US-9486506-B2 | Glucagon analogues | NOVO NORDISK A/S (DK) | 2016-11-08 | — | — | US | disclosed |
| US-20160310415-A1 | CONTROLLED RELEASE COMPOSITIONS FOR MODULATING FREE-RADICAL INDUCED DAMAGE AND METHODS OF USE THEREOF | OTONOMY, INC. | 2016-10-27 | — | — | US | disclosed |
| CN-105963710-A | Growth hormones with prolonged in-vivo efficacy | 诺沃—诺迪斯克保健股份有限公司 | 2016-09-28 | — | — | CN | disclosed |
| US-20160271263-A1 | Acylated Glucagon Analogues | NOVO NORDISK AS (DK) | 2016-09-22 | — | — | US | disclosed |
| WO-2016135291-A1 | IMMUNOTHERAPEUTIC TARGETING OF PLACENTAL-LIKE CHONDROITIN SULFATE USING CHIMERIC ANTIGEN RECEPTORS (CARS) AND IMMUNOTHERAPEUTIC TARGETING OF CANCER USING CARS WITH SPLIT-PROTEIN BINDING SYSTEMS | VAR2 PHARMACEUTICALS APS (DK) | 2016-09-01 | — | — | WO | disclosed |
| US-9427472-B2 | Controlled release compositions for modulating free-radical induced damage and methods of use thereof | OTONOMY, INC. (US) | 2016-08-30 | — | — | US | disclosed |
| US-20160243028-A1 | Auris Formulations for Treating Otic Diseases and Conditions | DOMPÉ FARMACEUTICI S.P.A. (IT) | 2016-08-25 | — | — | US | disclosed |
| US-9422368-B2 | Humanized anti-human NKG2A monoclonal antibody | NOVO NORDISK A/S (DK) | 2016-08-23 | — | — | US | disclosed |
| US-20160237116-A1 | SITE-SPECIFIC CHEMOENZYMATIC PROTEIN MODIFICATIONS | NOVARTIS AG | 2016-08-18 | — | — | US | disclosed |
| EP-1888118-B1 | POLYPEPTIDE FORMULATIONS STABILIZED WITH ETHYLENEDIAMINE | NOVO NORDISK AS (DK) | 2016-08-17 | — | — | EP | disclosed |
| US-20160228357-A1 | Auris Formulations for Treating Otic Diseases and Conditions | OTONOMY, INC. | 2016-08-11 | — | — | US | disclosed |
| EP-2222706-B2 | ANTIBODIES AGAINST HUMAN NKG2D AND USES THEREOF | NOVO NORDISK AS (DK) | 2016-08-10 | — | — | EP | disclosed |
| CN-102918056-B | Novel glucagon analogues | 诺沃—诺迪斯克有限公司 | 2016-08-10 | — | — | CN | disclosed |
| US-9409966-B2 | Glucagon-like peptide-1 derivatives and their pharmaceutical use | NOVO NORDISK A/S (DK) | 2016-08-09 | — | — | US | disclosed |
| CN-103215328-B | The joint of transglutaminase mediated peptide | 诺和诺德医疗保健公司 | 2016-08-03 | — | — | CN | disclosed |
| CN-103596583-B | novel glucagon analogues | 诺沃—诺迪斯克有限公司 | 2016-07-27 | — | — | CN | disclosed |
| US-9359400-B2 | Site-specific chemoenzymatic protein modifications | NOVARTIS AG (CH) | 2016-06-07 | — | — | US | disclosed |
| CN-105593238-A | Lysine-specific chemoenzymatic protein modification using microbial transglutaminase | NOVARTIS AG | 2016-05-18 | — | — | CN | disclosed |
| US-20160130573-A1 | Method of Controlling a Polypeptide Modification Reaction | NOVO NORDISK HEALTHCARE AG (CH) | 2016-05-12 | — | — | US | disclosed |
| US-20160120997-A1 | Modified Glycoproteins Having Circulating Half-Lives | NOVO NORDISK HEALTHCARE AG (CH) | 2016-05-05 | — | — | US | disclosed |
| US-20160108102-A1 | Novel GLP-1 Derivatives | NOVO NORDISK AS (DK) | 2016-04-21 | — | — | US | disclosed |
| US-20160095902-A1 | Auris Formulations for Treating Otic Diseases and Conditions | OTONOMY, INC. | 2016-04-07 | — | — | US | disclosed |
| US-20160067179-A1 | CONTROLLED RELEASE ANTIMICROBIAL COMPOSITIONS AND METHODS FOR THE TREATMENT OF OTIC DISORDERS | ALK-ABELLÓ, INC. | 2016-03-10 | — | — | US | disclosed |
| US-20160051547-A1 | CONTROLLED RELEASE ANTIMICROBIAL COMPOSITIONS AND METHODS FOR THE TREATMENT OF OTIC DISORDERS | ALK-ABELLÓ, INC. | 2016-02-25 | — | — | US | disclosed |
| US-20160046712-A1 | KIR-BINDING AGENTS AND METHODS OF USE THEREOF | NOVO NORDISK AS NOVO ALLÉ (DK) | 2016-02-18 | — | — | US | disclosed |
| US-20160038594-A1 | CONTROLLED RELEASE ANTIMICROBIAL COMPOSITIONS AND METHODS FOR THE TREATMENT OF OTIC DISORDERS | ALK-ABELLÓ, INC. | 2016-02-11 | — | — | US | disclosed |
| US-20160024214-A1 | Antibodies Against Human NKG2D and Uses Thereof | NOVO NORDISK AS (DK) | 2016-01-28 | — | — | US | disclosed |
| US-9233068-B2 | Controlled release antimicrobial compositions and methods for the treatment of OTIC disorders | OTONOMY, INC. (US) | 2016-01-12 | — | — | US | disclosed |
| US-20160002311-A1 | Novel Glucagon Analogues | NOVO NORDISK AS (DK) | 2016-01-07 | — | — | US | disclosed |
| US-20150368313-A1 | Novel Glucagon Analogues | NOVO NORDISK AS (DK) | 2015-12-24 | — | — | US | disclosed |
| EP-2330126-B1 | Protracted exendin-4 compounds | NOVO NORDISK AS (DK) | 2015-12-23 | — | — | EP | disclosed |
| EP-1765408-B1 | POLYPEPTIDE PROTRACTING TAGS COMPRISING A TETRAZOLE MOIETY | NOVO NORDISK AS (DK) | 2015-12-09 | — | — | EP | disclosed |
| US-9205048-B2 | Controlled release antimicrobial compositions and methods for the treatment of otic disorders | OTONOMY, INC. (US) | 2015-12-08 | — | — | US | disclosed |
| US-20150344576-A1 | HUMAN ANTI-KIR ANTIBODIES | NOVO NORDISK AS NOVO ALLE (DK) | 2015-12-03 | — | — | US | disclosed |
| US-9175061-B2 | Protein conjugates and methods for their preparation | NOVO NORDISK HEALTH CARE AG (CH) | 2015-11-03 | — | — | US | disclosed |
| EP-2932981-A2 | Albumin-binding derivatives of GLP-1 | NOVO NORDISK A/S (DK) | 2015-10-21 | — | — | EP | disclosed |
| US-20150274801-A1 | ACYLATED GLUCAGON ANALOGUES | NOVO NORDISK AS (DK) | 2015-10-01 | — | — | US | disclosed |
| EP-2322546-B1 | Acylated GLP-1 compounds | NOVO NORDISK AS (DK) | 2015-09-30 | — | — | EP | disclosed |
| US-9132087-B2 | Auris formulations for treating otic diseases and conditions | OTONOMY, INC. (US) | 2015-09-15 | — | — | US | disclosed |
| US-9127064-B2 | Antibodies against human NKG2D and uses thereof | NOVO NORDISK A/S (DK) | 2015-09-08 | — | — | US | disclosed |
| US-20150210743-A1 | CHIMERIC INHIBITOR MOLECULES OF COMPLEMENT ACTIVATION | OMEROS CORPORATION | 2015-07-30 | — | — | US | disclosed |
| EP-2190873-B1 | TRUNCATED GLP-1 DERIVATIVES AND THEIR THERAPEUTICAL USE | NOVO NORDISK AS (DK) | 2015-07-22 | — | — | EP | disclosed |
| US-20150191547-A1 | HUMAN ANTI-KIR ANTIBODIES | NOVO NORDISK AS NOVO ALLE (DK) | 2015-07-09 | — | — | US | disclosed |
| EP-2285829-B1 | METHOD OF CONTROLLING A POLYPEPTIDE MODIFICATION REACTION | NOVO NORDISK HEALTHCARE AG (CH) | 2015-07-08 | — | — | EP | disclosed |
| US-20150182594-A1 | NOVEL GLUCAGON ANALOGUES | NOVO NORDISK AS (DK) | 2015-07-02 | — | — | US | disclosed |
| US-9067977-B2 | Peptides derivatized with A-B-C-D- and their therapeutical use | NOVO NORDISK A/S (DK) | 2015-06-30 | — | — | US | disclosed |
| US-9061067-B2 | Polypeptide protracting tags | NOVO NORDISK A/S (DK) | 2015-06-23 | — | — | US | disclosed |
| US-20150150793-A1 | Controlled Release Antimicrobial Compositions and Methods for the Treatment of Otic Disorders | ALK-ABELLÓ, INC. | 2015-06-04 | — | — | US | disclosed |
| US-20150148317-A1 | SPINAL CORD INJURY, INFLAMMATION, AND IMMUNE-DISEASE: LOCAL CONTROLLED RELEASE OF THERAPEUTIC AGENTS | INVIVO THERAPEUTICS CORPORATION (US) | 2015-05-28 | — | — | US | disclosed |
| US-9029325-B2 | Amylin analogues and pharmaceutical compositions thereof | NOVO NORDISK A/S (DK) | 2015-05-12 | — | — | US | disclosed |
| US-9023789-B2 | Amylin analogs and pharmaceutical compositions thereof | NOVO NORDISK A/S (DK) | 2015-05-05 | — | — | US | disclosed |
| US-9018366-B2 | KIR-binding agents and methods of use thereof | Innate Pharma S.A.S (FR) | 2015-04-28 | — | — | US | disclosed |
| US-20150110783-A1 | ANTAGONIST ANTI-CD40 ANTIBODY PHARMACEUTICAL COMPOSITIONS | XOMA TECHNOLOGY LTD. (US) | 2015-04-23 | — | — | US | disclosed |
| EP-2289560-B1 | POLYPEPTIDE PROTRACTING TAGS COMPRISING A TETRAZOLE MOIETY | NOVO NORDISK AS (DK) | 2015-04-22 | — | — | EP | disclosed |
| US-9012398-B2 | Acylated exendin-4 compounds | NOVO NORDISK A/S (DK) | 2015-04-21 | — | — | US | disclosed |
| US-8981065-B2 | Human anti-KIR antibodies | Novo Nordisk A/S—Novo Alle (DK) | 2015-03-17 | — | — | US | disclosed |
| US-20150071929-A1 | ANTI-NKG2A ANTIBODIES AND USES THEREOF | NOVO NORDISK A/S (DK) | 2015-03-12 | — | — | US | disclosed |
| EP-2842576-A1 | Transglutaminase mediated conjugation of peptides | Novo Nordisk Health Care AG (CH) | 2015-03-04 | — | — | EP | disclosed |
| EP-2838914-A1 | HUMAN AMYLIN ANALOGUES | Novo Nordisk A/S (DK) | 2015-02-25 | — | — | EP | disclosed |
| US-20150038417-A1 | GLP-1 Agonists | NOVO NORDISK A/S | 2015-02-05 | — | — | US | disclosed |
| US-8945564-B2 | Antagonist anti-CD40 antibody pharmaceutical compositions | NOVARTIS AG (CH) | 2015-02-03 | — | — | US | disclosed |
| US-20150025003-A1 | GLUCAGON-LIKE PEPTIDE-1 DERIVATIVES AND THEIR PHARMACEUTICAL USE | NOVO NORDISK AS (DK) | 2015-01-22 | — | — | US | disclosed |
| US-20150004099-A1 | TARGETING OF CHONDROITIN SULFATE GLYCANS | VAR2 PHARMACEUTICALS APS (DK) | 2015-01-01 | — | — | US | disclosed |
| EP-2190460-B1 | PEPTIDES DERIVATIZED WITH A-B-C-D- AND THEIR THERAPEUTICAL USE | NOVO NORDISK AS (DK) | 2014-12-17 | — | — | EP | disclosed |
| EP-2812024-A1 | TARGETING OF CHONDROITIN SULFATE GLYCANS | Var2 Pharmaceuticals ApS (DK) | 2014-12-17 | — | — | EP | disclosed |
| EP-2811017-A2 | Hyperglycosylated human coagulation factor IX | Novo Nordisk Health Care AG (CH) | 2014-12-10 | — | — | EP | disclosed |
| EP-2038306-B1 | ANTI-NKG2A ANTIBODIES AND USES THEREOF | NOVO NORDISK AS (DK) | 2014-12-03 | — | — | EP | disclosed |
| EP-2059527-B1 | MODIFIED GLYCOPROTEINS | NOVO NORDISK HEALTHCARE AG (CH) | 2014-12-03 | — | — | EP | disclosed |
| US-8901283-B2 | Anti-NKG2A antibodies and uses thereof | NOVO NORDISK A/S (DK) | 2014-12-02 | — | — | US | disclosed |
| US-8895504-B2 | Amylin derivatives | NOVO NORDISK A/S (DK) | 2014-11-25 | — | — | US | disclosed |
| US-8895694-B2 | Glucagon-Like Peptide-1 derivatives and their pharmaceutical use | NOVO NORDISK A/S (DK) | 2014-11-25 | — | — | US | disclosed |
| US-20140341896-A1 | HUMANIZED ANTI-HUMAN NKG2A MONOCLONAL ANTIBODY | NOVO NORDISK A/S (DK) | 2014-11-20 | — | — | US | disclosed |
| US-20140329750-A1 | Growth Hormones with Prolonged In-Vivo Efficacy | NOVO NORDISK HEALTHCARE AG (CH) | 2014-11-06 | — | — | US | disclosed |
| EP-2571897-B1 | NOVEL GLUCAGON LIKE PEPTIDE ANALOGS, COMPOSITION, AND METHOD OF USE | BETTA PHARMACEUTICALS CO LTD (CN) | 2014-11-05 | — | — | EP | disclosed |
| US-8871714-B2 | Hyperglycosylated human coagulation factor IX | NOVO NORDISK HEALTH CARE AG (CH) | 2014-10-28 | — | — | US | disclosed |
| US-8865868-B2 | Conjugated proteins with prolonged in vivo efficacy | NOVO NORDISK HEALTHCARE AG (CH) | 2014-10-21 | — | — | US | disclosed |
| EP-2788027-A2 | GLP-1 AGONISTS | Novo Nordisk A/S (DK) | 2014-10-15 | — | — | EP | disclosed |
| US-8859731-B2 | Selective modification of proteins | NOVO NORDISK A/S (DK) | 2014-10-14 | — | — | US | disclosed |
| US-20140296131-A1 | Truncated GLP-1 Derivatives and Their Therapeutical Use | NOVO NORDISK A/S (DK) | 2014-10-02 | — | — | US | disclosed |
| US-8841249-B2 | Growth hormones with prolonged in-vivo efficacy | NOVO NORDISK A/S (DK) | 2014-09-23 | — | — | US | disclosed |
| US-20140243425-A1 | CONTROLLED RELEASE COMPOSITIONS FOR MODULATING FREE-RADICAL INDUCED DAMAGE AND METHODS OF USE THEREOF | OTONOMY, INC. (US) | 2014-08-28 | — | — | US | disclosed |
| EP-2769993-A1 | Antibodies against human NKG2D and uses thereof | NOVO NORDISK A/S (DK) | 2014-08-27 | — | — | EP | disclosed |
| US-8796427-B2 | Humanized anti-human NKG2A monoclonal antibody | NOVO NORDISK A/S (DK) | 2014-08-05 | — | — | US | disclosed |
| EP-2758426-A1 | NOVEL GLUCAGON ANALOGUES | Novo Nordisk A/S (DK) | 2014-07-30 | — | — | EP | disclosed |
| US-8784870-B2 | Controlled release compositions for modulating free-radical induced damage and methods of use thereof | OTONOMY, INC. (US) | 2014-07-22 | — | — | US | disclosed |
| US-8778874-B2 | Glycopeptide antibiotic monomer derivatives | NATIONAL UNIVERSITY CORPORATION NAGOYA UNIVERSITY (JP) | 2014-07-15 | — | — | US | disclosed |
| US-8779109-B2 | Growth hormones with prolonged in-vivo efficacy | NOVO NORDISK HEALTH CARE AG (CH) | 2014-07-15 | — | — | US | disclosed |
| US-8772232-B2 | Protracted exendin-4 compounds | NOVO NORDISK A/S (DK) | 2014-07-08 | — | — | US | disclosed |
| US-8741836-B2 | Polypeptides | NOVO NORDISK A/S (DK) | 2014-06-03 | — | — | US | disclosed |
| US-8722849-B2 | Polypeptides | NOVO NORDISK A/S (DK) | 2014-05-13 | — | — | US | disclosed |
| EP-2726505-A1 | THERAPEUTIC TARGETING OF FICOLIN-3 | Rigshospitalet (DK) | 2014-05-07 | — | — | EP | disclosed |
| EP-1863521-B1 | EXTENDED GLP-1 COMPOUNDS | NOVO NORDISK AS (DK) | 2014-05-07 | — | — | EP | disclosed |
| US-20140120105-A1 | THERAPEUTIC TARGETING OF FICOLIN-3 | KOBENHAVNS UNIVERSITET (DK) | 2014-05-01 | — | — | US | disclosed |
| CN-1997670-B | Human anti-KIR antibodies | NOVO NORDISK AS | 2014-04-30 | — | — | CN | disclosed |
| EP-2222706-B1 | ANTIBODIES AGAINST HUMAN NKG2D AND USES THEREOF | NOVO NORDISK AS (DK) | 2014-04-23 | — | — | EP | disclosed |
| US-20140107324-A1 | Growth Hormones with Prolonged In-Vivo Efficacy | NOVO NORDISK HEALTH CARE AG (CH) | 2014-04-17 | — | — | US | disclosed |
| EP-2718314-A2 | POLYPEPTIDES | Novo Nordisk A/S (DK) | 2014-04-16 | — | — | EP | disclosed |
| EP-2718316-A1 | POLYPEPTIDES | Novo Nordisk A/S (DK) | 2014-04-16 | — | — | EP | disclosed |
| EP-2718315-A2 | POLYPEPTIDES | Novo Nordisk A/S (DK) | 2014-04-16 | — | — | EP | disclosed |
| US-8697844-B2 | Method of purifying pegylated proteins | NOVO NORDISK A/S (DK) | 2014-04-15 | — | — | US | disclosed |
| US-20140087995-A1 | Polypeptides | NOVO NORDISK A/S (DK) | 2014-03-27 | — | — | US | disclosed |
| US-8648119-B2 | Controlled release immunomodulator compositions and methods for the treatment of otic disorders | OTONOMY, INC. (US) | 2014-02-11 | — | — | US | disclosed |
| EP-2691108-A1 | NOVEL GLUCAGON ANALOGUES | Novo Nordisk A/S (DK) | 2014-02-05 | — | — | EP | disclosed |
| US-20140031278-A1 | Novel Glucagon Analogues | NOVO NORDISK A/S (DK) | 2014-01-30 | — | — | US | disclosed |
| US-20140018286-A1 | AMYLIN ANALOGUES AND PHARMACEUTICAL COMPOSITIONS THEREOF | NOVO NORDISK A/S (DK) | 2014-01-16 | — | — | US | disclosed |
| CN-103509111-A | Human anti-KIR antibodies | NOVO NORDISK AS | 2014-01-15 | — | — | CN | disclosed |
| US-20140011732-A1 | Peptides Derivatized with A-B-C-D- and their Therapeutical Use | NOVO NORDISK A/S (DK) | 2014-01-09 | — | — | US | disclosed |
| US-8614307-B2 | Nucleic acids encoding human anti-kir antibodies | Novo-Nordisk A/S—Novo Alle (DK) | 2013-12-24 | — | — | US | disclosed |
| US-8603972-B2 | Extended GLP-1 compounds | NOVO NORDISK A/S (DK) | 2013-12-10 | — | — | US | disclosed |
| US-20130324509-A1 | SPINAL CORD INJURY, INFLAMMATION, AND IMMUNE-DISEASE: LOCAL CONTROLLED RELEASE OF THERAPEUTIC AGENTS | INVIVO THERAPEUTICS CORPORATION (US) | 2013-12-05 | — | — | US | disclosed |
| US-20130324500-A1 | SPINAL CORD INJURY, INFLAMMATION AND IMMUNE-DISEASE: LOCAL CONTROLLED RELEASE OF THERAPEUTIC AGENTS | INVIVO THERAPEUTICS CORPORATION (US) | 2013-12-05 | — | — | US | disclosed |
| US-8586532-B2 | Method for selectively modifying a protein via transglutaminase catalyzed reaction | NOVO NORDISK HEALTHCARE A/G (CH) | 2013-11-19 | — | — | US | disclosed |
| US-8575091-B1 | Amylin analogues and pharmaceutical compositions thereof | NOVO NORDISK A/S (DK) | 2013-11-05 | — | — | US | disclosed |
| US-8575090-B2 | Amylin analogues and pharmaceutical compositions thereof | NOVO NORDISK A/S (DK) | 2013-11-05 | — | — | US | disclosed |
| US-20130288958-A1 | Novel Glucagon Analogues | NOVO NORDISK AS (DK) | 2013-10-31 | — | — | US | disclosed |
| US-20130287770-A1 | HUMAN ANTI-KIR ANITBODIES | INNATE PHARMA SAS (FR) | 2013-10-31 | — | — | US | disclosed |
| US-20130281363-A1 | POLYPEPTIDES | NOVO NORDISK A/S (DK) | 2013-10-24 | — | — | US | disclosed |
| WO-2013156594-A1 | HUMAN AMYLIN ANALOGUES | NOVO NORDISK A/S (DK) | 2013-10-24 | — | — | WO | disclosed |
| EP-2641611-A2 | Combination therapy | Novo Nordisk A/S (DK) | 2013-09-25 | — | — | EP | disclosed |
| US-8541368-B2 | Glucagon analogues | NOVO NORDISK A/S (DK) | 2013-09-24 | — | — | US | disclosed |
| US-20130243770-A1 | TREATING DIABETES USING INHIBITORS OF IL-1 | NOVO NORDISK A/S (DK) | 2013-09-19 | — | — | US | disclosed |
| US-20130244931-A1 | Novel GLP-1 Derivatives | NOVO NORDISK AS (DK) | 2013-09-19 | — | — | US | disclosed |
| EP-2360181-B1 | IL-21 variants | NOVO NORDISK AS (DK) | 2013-09-18 | — | — | EP | disclosed |
| US-8536122-B2 | Acylated GLP-1 compounds | NOVO NORDISK A/S (DK) | 2013-09-17 | — | — | US | disclosed |
| EP-2633866-A2 | Combination therapy | Novo Nordisk A/S (DK) | 2013-09-04 | — | — | EP | disclosed |
| US-20130216609-A1 | Controlled Release Antimicrobial Compositions and Methods for the Treatment of Otic Disorders | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2013-08-22 | — | — | US | disclosed |
| US-20130217616-A1 | CHIMERIC INHIBITOR MOLECULES OF COMPLEMENT ACTIVATION | OMEROS CORPORATION | 2013-08-22 | — | — | US | disclosed |
| EP-2628753-A1 | Humanized anti-human NKG2A monoclonal antibody | Novo Nordisk A/S (DK) | 2013-08-21 | — | — | EP | disclosed |
| WO-2013117705-A1 | TARGETING OF CHONDROITIN SULFATE GLYCANS | VAR2 PHARMACEUTICALS APS (DK) | 2013-08-15 | — | — | WO | disclosed |
| US-20130203672-A1 | Novel Glucagon Like Peptide Analogs, Composition, and Method of Use | BETTA PHARMACEUTICALS CO., LTD (CN) | 2013-08-08 | — | — | US | disclosed |
| EP-1680138-B1 | COMBINATION THERAPY | NOVO NORDISK AS (DK) | 2013-07-17 | — | — | EP | disclosed |
| US-8486890-B2 | Amylin derivatives | NOVO NORDISK A/S (DK) | 2013-07-16 | — | — | US | disclosed |
| US-8481696-B2 | Glycosylated glycopeptide antibiotic derivatives | SHIONOGI & CO., LTD. (JP) | 2013-07-09 | — | — | US | disclosed |
| US-8481696-B2 | Glycosylated glycopeptide antibiotic derivatives | SHIONOGI & CO., LTD. (JP) | 2013-07-09 | — | — | US | disclosed |
| US-8470964-B2 | Peptides derived from NCAM (FGLs) | ENKAM PHARMACEUTICALS A/S (DK) | 2013-06-25 | — | — | US | disclosed |
| WO-2013083826-A2 | GLP-1 AGONISTS | NOVO NORDISK A/S (DK) | 2013-06-13 | — | — | WO | disclosed |
| US-20130143798-A1 | NOVEL GLUCAGON ANALOGUES | NOVO NORDISK A/S (DK) | 2013-06-06 | — | — | US | disclosed |
| US-20130143269-A1 | KIR-Binding Agents and Methods of Use Thereof | Innate Pharma S.A.S (FR) | 2013-06-06 | — | — | US | disclosed |
| CN-103124739-A | Novel glucagon like peptide analogs, composition, and method of use | ZHEJIANG BETA PHARMA INC | 2013-05-29 | — | — | CN | disclosed |
| CN-102112157-B | Conjugated proteins with prolonged in vivo efficacy | NOVO NORDISK AS | 2013-05-29 | — | — | CN | disclosed |
| US-8450459-B2 | IL-21 derivatives and variants | NOVO NORDISK A/S (DK) | 2013-05-28 | — | — | US | disclosed |
| US-20130116210-A1 | CONTROLLED RELEASE ANTIMICROBIAL COMPOSITIONS AND METHODS FOR THE TREATMENT OF OTIC DISORDERS | OTONOMY, INC. (US) | 2013-05-09 | — | — | US | disclosed |
| US-20130095555-A1 | Hyperglycosylated Human Coagulation Factor IX | NOVO NORDISK A/S (DK) | 2013-04-18 | — | — | US | disclosed |
| EP-1750751-B1 | STABILIZED INTERFERON LIQUID FORMULATIONS | ARES TRADING SA (CH) | 2013-04-10 | — | — | EP | disclosed |
| WO-2013041678-A1 | NOVEL GLUCAGON ANALOGUES | NOVO NORDISK A/S (DK) | 2013-03-28 | — | — | WO | disclosed |
| US-20130079278-A1 | Novel Glucagon Analogues | NOVO NORDISK A/S (DK) | 2013-03-28 | — | — | US | disclosed |
| EP-2571897-A1 | NOVEL GLUCAGON LIKE PEPTIDE ANALOGS, COMPOSITION, AND METHOD OF USE | Zhejiang Beta Pharma Inc. (CN) | 2013-03-27 | — | — | EP | disclosed |
| CN-103002918-A | Growth hormone with prolonged in vivo efficacy | NOVO NORDISK HEALTHCARE AG | 2013-03-27 | — | — | CN | disclosed |
| US-20130071383-A1 | SELECTIVE MODIFICATION OF PROTEINS | NOVO NORDISK A/S (DK) | 2013-03-21 | — | — | US | disclosed |
| US-20130071351-A1 | COMBINATION THERAPY | MOLLER NIELS PETER HUNDAHL (DK) | 2013-03-21 | — | — | US | disclosed |
| US-20130059770-A1 | POLYPEPTIDES | NOVO NORDISK A/S (DK) | 2013-03-07 | — | — | US | disclosed |
| EP-2057189-B1 | ACYLATED EXENDIN-4 COMPOUNDS | NOVO NORDISK AS (DK) | 2013-03-06 | — | — | EP | disclosed |
| US-8388970-B2 | KIR-binding agents and methods of use thereof | NOVO NORDISK A/S (DK) | 2013-03-05 | — | — | US | disclosed |
| US-20130053315-A1 | NOVEL GLP-1 DERIVATIVES | NOVO NORDISK A/S | 2013-02-28 | — | — | US | disclosed |
| US-20130053310-A1 | NOVEL GLUCAGON ANALOGUES | NOVO NORDISK A/S (DK) | 2013-02-28 | — | — | US | disclosed |
| EP-2560686-A2 | SELECTIVE MODIFICATION OF PROTEINS | NOVO NORDISK A/S (DK) | 2013-02-27 | — | — | EP | disclosed |
| US-8383776-B2 | Purification of factor XIII polypeptides from biological materials | NOVO NORDISK HEALTH CARE AG (CH) | 2013-02-26 | — | — | US | disclosed |
| US-8383367-B2 | IL-21 variant nucleic acids | NOVO NORDISK A/S (DK) | 2013-02-26 | — | — | US | disclosed |
| CN-102939110-A | Selective modification of proteins | NOVO NORDISK AS | 2013-02-20 | — | — | CN | disclosed |
| US-20130040884-A1 | ALBUMIN-BINDING CONJUGATES COMPRISING FATTY-ACID AND PEG | NOVO NORDISK A/S | 2013-02-14 | — | — | US | disclosed |
| CN-102933598-A | Novel glucagon analogues | NOVO NORDISK AS | 2013-02-13 | — | — | CN | disclosed |
| US-20130035285-A1 | NOVEL GLUCAGON ANALOGUES | NOVO NORDISK A/S (DK) | 2013-02-07 | — | — | US | disclosed |
| EP-2552952-A1 | NOVEL GLUCAGON ANALOGUES | NOVO NORDISK A/S (DK) | 2013-02-06 | — | — | EP | disclosed |
| EP-2552950-A1 | NOVEL GLUCAGON ANALOGUES | Novo Nordisk A/S (DK) | 2013-02-06 | — | — | EP | disclosed |
| EP-2552951-A1 | NOVEL GLUCAGON ANALOGUES | Novo Nordisk A/S (DK) | 2013-02-06 | — | — | EP | disclosed |
| CN-102918056-A | Novel glucagon analogues | NOVO NORDISK AS | 2013-02-06 | — | — | CN | disclosed |
| CN-102918055-A | Novel glucagon analogues | NOVO NORDISK AS | 2013-02-06 | — | — | CN | disclosed |
| US-20130012432-A1 | Peptides for Treatment of Obesity | NOVO NORDISK A/S (DK) | 2013-01-10 | — | — | US | disclosed |
| US-20130012427-A1 | POLYPEPTIDES | NOVO NORDISK A/S (DK) | 2013-01-10 | — | — | US | disclosed |
| EP-2542569-A1 | CHIMERIC INHIBITOR MOLECULES OF COMPLEMENT ACTIVATION | Rigshospitalet (DK) | 2013-01-09 | — | — | EP | disclosed |
| US-20130005646-A1 | POLYPEPTIDES | NOVO NORDISK A/S (DK) | 2013-01-03 | — | — | US | disclosed |
| WO-2013000471-A1 | THERAPEUTIC TARGETING OF FICOLIN-3 | RIGSHOSPITALET (DK) | 2013-01-03 | — | — | WO | disclosed |
| EP-2539364-A1 | PEPTIDES FOR TREATMENT OF OBESITY | Novo Nordisk A/S (DK) | 2013-01-02 | — | — | EP | disclosed |
| EP-2398822-B1 | MODIFICATION OF FACTOR VIII | NOVO NORDISK AS (DK) | 2013-01-02 | — | — | EP | disclosed |
| WO-2012168431-A2 | POLYPEPTIDES | NOVO NORDISK A/S (DK) | 2012-12-13 | — | — | WO | disclosed |
| WO-2012168430-A2 | POLYPEPTIDES | NOVO NORDISK A/S (DK) | 2012-12-13 | — | — | WO | disclosed |
| WO-2012168432-A1 | POLYPEPTIDES | NOVO NORDISK A/S (DK) | 2012-12-13 | — | — | WO | disclosed |
| US-20120309944-A1 | Growth Hormones With Prolonged In-Vivo Efficacy | NOVO NORDISK HEALTH CARE AG (CH) | 2012-12-06 | — | — | US | disclosed |
| US-8318817-B2 | Controlled release antimicrobial compositions and methods for the treatment of otic disorders | OTONOMY, INC. (US) | 2012-11-27 | — | — | US | disclosed |
| US-20120295847-A1 | Acylated GLP-1 Compounds | NOVO NORDISK A/S (DK) | 2012-11-22 | — | — | US | disclosed |
| US-20120289453-A1 | NOVEL GLP-1 COMPOUNDS | NOVO NORDISK A/S (DK) | 2012-11-15 | — | — | US | disclosed |
| US-20120282285-A1 | MASP ISOFORMS AS INHIBITORS OF COMPLEMENT ACTIVATION | RIGSHOSPITALET (DK) | 2012-11-08 | — | — | US | disclosed |
| US-20120283170-A1 | Acylated Exendin-4 Compounds | NOVO NORDISK A/S (DK) | 2012-11-08 | — | — | US | disclosed |
| EP-2033662-B1 | Transglutaminase mediated conjugation of peptides | NOVO NORDISK HEALTHCARE AG (CH) | 2012-10-17 | — | — | EP | disclosed |
| WO-2012130866-A1 | NOVEL GLUCAGON ANALOGUES | NOVO NORDISK A/S (DK) | 2012-10-04 | — | — | WO | disclosed |
| US-20120244137-A1 | Method of Purifying Pegylated Proteins | NOVO NORDISK HEALTH CARE AG (CH) | 2012-09-27 | — | — | US | disclosed |
| US-20120237510-A1 | Anti-NKG2A Antibodies and Uses Thereof | NOVO NORDISK A/S (DK) | 2012-09-20 | — | — | US | disclosed |
| US-20120208237-A1 | HUMAN ANTI-KIR ANTIBODIES | Innate Pharma S.A.S (FR) | 2012-08-16 | — | — | US | disclosed |
| US-8222376-B2 | KIR-binding agents and methods of use thereof | NOVO NORDISK A/S (DK) | 2012-07-17 | — | — | US | disclosed |
| US-20120172303-A1 | Growth Hormones with Prolonged In-Vivo Efficacy | NOVO NORDISK HEALTH CARE AG (CH) | 2012-07-05 | — | — | US | disclosed |
| US-8206709-B2 | Anti-NKG2A antibodies and uses thereof | NOVO NORDISK A/S (DK) | 2012-06-26 | — | — | US | disclosed |
| EP-1799711-B1 | PROTRACTED EXENDIN-4 COMPOUNDS | NOVO NORDISK AS (DK) | 2012-06-20 | — | — | EP | disclosed |
| EP-2454281-A2 | MASP ISOFORMS AS INHIBITORS OF COMPLEMENT ACTIVATION | Rigshospitalet (DK) | 2012-05-23 | — | — | EP | disclosed |
| EP-2444491-A2 | Hyperglycosylated human coagulation factor IX | Novo Nordisk Health Care AG (CH) | 2012-04-25 | — | — | EP | disclosed |
| US-20120088716-A1 | Polypeptide Protracting Tags | NOVO NORDISK A/S (DK) | 2012-04-12 | — | — | US | disclosed |
| US-20120082996-A1 | IL-21 VARIANTS | HJORTH SIV ANNEGRETHE (DK) | 2012-04-05 | — | — | US | disclosed |
| EP-1708755-B1 | TRANSGLUTAMINASE MEDIATED CONJUGATION OF PEPTIDES | NOVO NORDISK HEALTHCARE AG (CH) | 2012-03-21 | — | — | EP | disclosed |
| EP-2426150-A1 | Anti-NKG2A antibodies and uses thereof | Novo Nordisk A/S (DK) | 2012-03-07 | — | — | EP | disclosed |
| US-8129343-B2 | Acylated GLP-1 compounds | NOVO NORDISK A/S (DK) | 2012-03-06 | — | — | US | disclosed |
| US-8119775-B2 | Human anti-KIR antibodies | UNIVERSITY OF GENOA (IT) | 2012-02-21 | — | — | US | disclosed |
| EP-1750750-B1 | METHOD OF STABILIZING PROTEINS | ARES TRADING SA (CH) | 2012-02-01 | — | — | EP | disclosed |
| US-20120021973-A1 | Peptides for Treatment of Obesity | NOVO NORDISK A/S (DK) | 2012-01-26 | — | — | US | disclosed |
| US-8097584-B2 | Therapeutic mixture comprising insulin, ethylenediamine and an antimicrobial preservative; improved chemical and storage stability | NOVO NORDISK A/S (DK) | 2012-01-17 | — | — | US | disclosed |
| EP-2398822-A1 | MODIFICATION OF FACTOR VIII | Novo Nordisk A/S (DK) | 2011-12-28 | — | — | EP | disclosed |
| US-20110306551-A1 | Modification of Factor VIII | NOVO NORDISK A/S (DK) | 2011-12-15 | — | — | US | disclosed |
| US-20110301084-A1 | Protracted Exendin-4 Compounds | NOVO NORDISK A/S (DK) | 2011-12-08 | — | — | US | disclosed |
| WO-2011143788-A1 | NOVEL GLUCAGON LIKE PEPTIDE ANALOGS, COMPOSITION, AND METHOD OF USE | ZHEJIANG BETA PHARMA INC. (CN) | 2011-11-24 | — | — | WO | disclosed |
| US-20110275559-A1 | Long-Acting Y2 and/or Y4 Receptor Agonists | NOVO NORDISK A/S (DK) | 2011-11-10 | — | — | US | disclosed |
| US-20110269182-A1 | Method for Selectively Modifying a Protein | NOVO NORDISK A/S (DK) | 2011-11-03 | — | — | US | disclosed |
| EP-1836225-B1 | KIR-BINDING AGENTS AND METHODS OF USE THEREOF | NOVO NORDISK AS (DK) | 2011-11-02 | — | — | EP | disclosed |
| WO-2011131510-A2 | SELECTIVE MODIFICATION OF PROTEINS | NOVO NORDISK A/S (DK) | 2011-10-27 | — | — | WO | disclosed |
| US-8034326-B2 | IL-21 variants | NOVO NORDISK A/S (DK) | 2011-10-11 | — | — | US | disclosed |
| EP-2370104-A1 | PEPTIDES FOR TREATMENT OF OBESITY | Novo Nordisk A/S (DK) | 2011-10-05 | — | — | EP | disclosed |
| US-8030273-B2 | Lysine residue of analog acylated with a diacid; substituted for an amino acid residue in [N-epsilon(17-carboxyheptadecanoic acid)20 exendin-4(1-39)-amide; hyperglycemia, type 2 diabetes, impaired glucose tolerance, type 1 diabetes, obesity, hypertension, syndrome X, dyslipidemia, cognitive disorders | NOVO NORDISK A/S (DK) | 2011-10-04 | — | — | US | disclosed |
| WO-2011117417-A1 | NOVEL GLUCAGON ANALOGUES | NOVO NORDISK A/S (DK) | 2011-09-29 | — | — | WO | disclosed |
| WO-2011117416-A1 | NOVEL GLUCAGON ANALOGUES | NOVO NORDISK A/S (DK) | 2011-09-29 | — | — | WO | disclosed |
| WO-2011117415-A1 | NOVEL GLUCAGON ANALOGUES | NOVO NORDISK A/S (DK) | 2011-09-29 | — | — | WO | disclosed |
| EP-2368579-A1 | Transglutaminase mediated conjugation of peptides | Novo Nordisk Health Care AG (CH) | 2011-09-28 | — | — | EP | disclosed |
| US-20110223151-A1 | CONJUGATED PROTEINS WITH PROLONGED IN VIVO EFFICACY | NOVO NORDISK HEALTH CARE AG (CH) | 2011-09-15 | — | — | US | disclosed |
| WO-2011107591-A1 | CHIMERIC INHIBITOR MOLECULES OF COMPLEMENT ACTIVATION | RIGSHOSPITALET (DK) | 2011-09-09 | — | — | WO | disclosed |
| WO-2011104378-A1 | PEPTIDES FOR TREATMENT OF OBESITY | NOVO NORDISK A/S (DK) | 2011-09-01 | — | — | WO | disclosed |
| WO-2011104379-A1 | PEPTIDES FOR TREATMENT OF OBESITY | NOVO NORDISK A/S (DK) | 2011-09-01 | — | — | WO | disclosed |
| EP-2360181-A1 | IL-21 variants | Novo Nordisk A/S (DK) | 2011-08-24 | — | — | EP | disclosed |
| EP-2346515-A1 | SPINAL CORD INJURY, INFLAMMATION, AND IMMUNE-DISEASE: LOCAL CONTROLLED RELEASE OF THERAPEUTIC AGENTS | Invivo Therapeutics Corporation (US) | 2011-07-27 | — | — | EP | disclosed |
| US-20110177580-A1 | Method of Controlling a Polypeptide Modification Reaction | NOVO NORDISK HEALTHCARE AG (CH) | 2011-07-21 | — | — | US | disclosed |
| EP-2340261-A1 | AMYLIN DERIVATIVES | Novo Nordisk A/S (DK) | 2011-07-06 | — | — | EP | disclosed |
| US-20110152183-A1 | DERIVATISED HYBRID PEPTIDES OF AMYLIN AND SALMON CALCITONIN | NOVO NORDISK A/S (DK) | 2011-06-23 | — | — | US | disclosed |
| US-20110144017-A1 | Protein conjugates and methods for their preparation | NOVO NORDISK HEALTH CARE AG (CH) | 2011-06-16 | — | — | US | disclosed |
| US-20110137011-A1 | HYPERGLYCOSYLATED HUMAN COAGULATION FACTOR IX | NOVO NORDISK A/S (DK) | 2011-06-09 | — | — | US | disclosed |
| EP-2330126-A1 | Protracted exendin-4 compounds | NOVO NORDISK A/S (DK) | 2011-06-08 | — | — | EP | disclosed |
| EP-2323694-A1 | CONJUGATED PROTEINS WITH PROLONGED IN VIVO EFFICACY | Novo Nordisk Health Care AG (CH) | 2011-05-25 | — | — | EP | disclosed |
| CN-102076353-A | Derivatised hybrid peptides of amylin and salmon calcitonin | NOVO NORDISK AS | 2011-05-25 | — | — | CN | disclosed |
| EP-2322546-A1 | Acylated GLP-1 compounds | NOVO NORDISK A/S (DK) | 2011-05-18 | — | — | EP | disclosed |
| US-20110105394-A1 | Amylin Derivatives | NOVO NORDISK A/S (DK) | 2011-05-05 | — | — | US | disclosed |
| US-20110098225-A1 | NOVEL PEPTIDES DERIVED FROM NCAM (FGLs) | COPENHAGEN UNIVERSITY | 2011-04-28 | — | — | US | disclosed |
| US-20110098213-A1 | Novel peptides for use in the treatment of obesity | NOVO NORDISK A/S (DK) | 2011-04-28 | — | — | US | disclosed |
| EP-2306975-A2 | CONTROLLED-RELEASE OTIC STRUCTURE MODULATING AND INNATE IMMUNE SYSTEM MODULATING COMPOSITIONS AND METHODS FOR THE TREATMENT OF OTIC DISORDERS | Otonomy, Inc. (US) | 2011-04-13 | — | — | EP | disclosed |
| US-20110082079-A1 | GLUCAGON-LIKE PEPTIDE-1 DERIVATIVES AND THEIR PHARMACEUTICAL USE | NOVO NORDISK A/S (DK) | 2011-04-07 | — | — | US | disclosed |
| EP-2293811-A1 | DERIVATISED HYBRID PEPTIDES OF AMYLIN AND SALMON CALCITONIN | Novo Nordisk A/S (DK) | 2011-03-16 | — | — | EP | disclosed |
| EP-2292272-A2 | Polypeptide protracting tags comprising a tetrazole moiety | NOVO NORDISK A/S (DK) | 2011-03-09 | — | — | EP | disclosed |
| US-20110052606-A1 | Humanized Anti-Human NKG2A Monoclonal Antibody | NOVO NORDISK A/S (DK) | 2011-03-03 | — | — | US | disclosed |
| EP-2289560-A2 | Polypeptide protracting tags comprising a tetrazole moiety | NOVO NORDISK A/S (DK) | 2011-03-02 | — | — | EP | disclosed |
| US-7897560-B2 | Plasma protein affinity tags | NOVO NORDISK A/S (DK) | 2011-03-01 | — | — | US | disclosed |
| US-20110046063-A1 | READY-TO-USE BIVALIRUDIN COMPOSITIONS | THE MEDICINES COMPANY | 2011-02-24 | — | — | US | disclosed |
| EP-2287195-A2 | Pan-KIR2DL NK-receptor antibodies and their use in diagnostik and therapy | Novo Nordisk A/S (DK) | 2011-02-23 | — | — | EP | disclosed |
| EP-1791868-B1 | ANTIBODIES BINDING TO RECEPTORS KIR2DL1, -2, 3 BUT NOT KIR2DS4 AND THEIR THERAPEUTIC USE | NOVO NORDISK AS (DK) | 2011-02-23 | — | — | EP | disclosed |
| US-7893017-B2 | Acylation; point mutations; site-directed mutagenesis; hyperglycemia; diabetes | NOVO NORDISK A/S (DK) | 2011-02-22 | — | — | US | disclosed |
| EP-1877439-B1 | IL-21 VARIANTS | NOVO NORDISK AS (DK) | 2011-02-09 | — | — | EP | disclosed |
| US-7883709-B2 | bacterial ADP-ribosylating exotoxin class protein (cholera toxin), arginine phosphate and 3-(3-Cholamidopropyl)-dimethylammonio-1-propanesulfonate; immunogens | NOVARTIS AG (CH) | 2011-02-08 | — | — | US | disclosed |
| EP-2279204-A1 | LONG-ACTING Y2 AND/OR Y4 RECEPTOR AGONISTS | Novo Nordisk A/S (DK) | 2011-02-02 | — | — | EP | disclosed |
| US-7879985-B2 | Antibodies against human NKG2D and uses thereof | NOVO NORDISK A/S (DK) | 2011-02-01 | — | — | US | disclosed |
| WO-2011006982-A2 | INHIBITORS OF COMPLEMENT ACTIVATION | RIGSHOSPITALET (DK) | 2011-01-20 | — | — | WO | disclosed |
| EP-2268807-A2 | HYPERGLYCOSYLATED HUMAN COAGULATION FACTOR IX | Novo Nordisk A/S (DK) | 2011-01-05 | — | — | EP | disclosed |
| US-7858082-B2 | Method of stabilizing proteins | ARES TRADING S.A. (CH) | 2010-12-28 | — | — | US | disclosed |
| EP-2263684-A1 | IL-21 derivatives | NOVO NORDISK A/S (DK) | 2010-12-22 | — | — | EP | disclosed |
| US-7855325-B2 | Use of nitric oxide modulators in Agrobacterium-mediated plant transformation | MONSANTO TECHNOLOGY LLC (US) | 2010-12-21 | — | — | US | disclosed |
| US-20100305032-A1 | Novel GLP-1 Derivatives | NOVO NORDISK A/S (DK) | 2010-12-02 | — | — | US | disclosed |
| US-20100297098-A1 | Purification of Factor XIII Polypeptides from Biological Materials | NOVO NORDISK HEALTHCARE A/G (CH) | 2010-11-25 | — | — | US | disclosed |
| US-20100292133-A1 | TRUNCATED GLP-1 DERIVATIES AND THEIR THERAPEUTICAL USE | NOVO NORDISK A/S (DK) | 2010-11-18 | — | — | US | disclosed |
| US-20100292444-A1 | Novel Prolactin Compounds | NOVO NORDISK A/S (DK) | 2010-11-18 | — | — | US | disclosed |
| US-20100286364-A1 | GLYCOSYLATED GLYCOPEPTIDE ANTIBIOTIC DERIVATIVES | SHIONOGI & CO., LTD. (JP) | 2010-11-11 | — | — | US | disclosed |
| US-20100286364-A1 | GLYCOSYLATED GLYCOPEPTIDE ANTIBIOTIC DERIVATIVES | SHIONOGI & CO., LTD. (JP) | 2010-11-11 | — | — | US | disclosed |
| EP-2247619-A1 | HUMANIZED ANTI-HUMAN NKG2A MONOCLONAL ANTIBODY | Novo Nordisk A/S (DK) | 2010-11-10 | — | — | EP | disclosed |
| US-20100272718-A1 | Antibodies Against Human NKG2D and Uses Thereof | NOVO NORDISK A/S (DK) | 2010-10-28 | — | — | US | disclosed |
| CN-101868476-A | Glucagon-like peptide-1 derivatives and their pharmaceutical use | NOVO NORDISK AS | 2010-10-20 | — | — | CN | disclosed |
| US-20100261637-A1 | PEPTIDES DERIVATIZED WITH A-B-C-D- AND THEIR THERAPEUTICAL USE | NOVO NORDISK A/S (DK) | 2010-10-14 | — | — | US | disclosed |
| CN-101855240-A | Improved derivatives of amylin | NOVO NORDISK AS | 2010-10-06 | — | — | CN | disclosed |
| US-7807142-B2 | Stabilized liquid polypeptide-containing pharmaceutical compositions | NOVARTIS VACCINES AND DIAGNOSTICS, INC. (US) | 2010-10-05 | — | — | US | disclosed |
| US-20100247526-A1 | Anti-NKG2A Antibodies and Uses Thereof | NOVO NORDISK A/S (DK) | 2010-09-30 | — | — | US | disclosed |
| US-20100249029-A1 | Peptides with high affinity for the prolactin receptor | NOVO NORDISK A/S (DK) | 2010-09-30 | — | — | US | disclosed |
| WO-2010102886-A1 | MODIFICATION OF FACTOR VIII | NOVO NORDISK A/S (DK) | 2010-09-16 | — | — | WO | disclosed |
| EP-1673387-B1 | IL-21 DERIVATIVES | NOVO NORDISK AS (DK) | 2010-09-15 | — | — | EP | disclosed |
| US-20100222269-A1 | IMPROVED DERIVATIVES OF AMYLIN | NOVO NORDISK A/S (DK) | 2010-09-02 | — | — | US | disclosed |
| EP-2222706-A1 | ANTIBODIES AGAINST HUMAN NKG2D AND USES THEREOF | Novo Nordisk A/S (DK) | 2010-09-01 | — | — | EP | disclosed |
| EP-2220108-A2 | PROTEIN PURIFICATION AND ENDOTOXIN REMOVAL | Novo Nordisk A/S (DK) | 2010-08-25 | — | — | EP | disclosed |
| CN-101809032-A | Method for selectively modifying proteins | NOVO NORDISK AS | 2010-08-18 | — | — | CN | disclosed |
| US-20100196481-A1 | SPINAL CORD INJURY, INFLAMMATION, AND IMMUNE-DISEASE: LOCAL CONTROLLED RELEASE OF THERAPEUTIC AGENTS | INVIVO THERAPEUTICS CORPORATION (US) | 2010-08-05 | — | — | US | disclosed |
| US-20100197573-A1 | Transglutaminase Mediated Conjugation of Growth Hormone | NOVO NORDISK HEALTH CARE AG (CH) | 2010-08-05 | — | — | US | disclosed |
| EP-1863839-B1 | ACYLATED GLP-1 COMPOUNDS | NOVO NORDISK AS (DK) | 2010-08-04 | — | — | EP | disclosed |
| EP-2213733-A2 | Factor IX analogues having prolonged in vivo half life | Novo Nordisk Health Care AG (CH) | 2010-08-04 | — | — | EP | disclosed |
| US-20100184641-A1 | Novel Plasma Protein Affinity Tags | NOVO NORDISK A/S (DK) | 2010-07-22 | — | — | US | disclosed |
| US-20100173835-A1 | Peptides for Treatment of Obesity | NOVO NORDISK A/S (DK) | 2010-07-08 | — | — | US | disclosed |
| US-7731948-B2 | Stabilized interferon liquid formulations | ARES TRADING S.A. (CH) | 2010-06-08 | — | — | US | disclosed |
| WO-2010060901-A1 | PEPTIDES FOR TREATMENT OF OBESITY | NOVO NORDISK A/S (DK) | 2010-06-03 | — | — | WO | disclosed |
| US-20100135901-A1 | COMBINATION THERAPY | MOLLER NIELS PETER HUNDAHL | 2010-06-03 | — | — | US | disclosed |
| EP-2190871-A1 | IMPROVED DERIVATIVES OF AMYLIN | Novo Nordisk A/S (DK) | 2010-06-02 | — | — | EP | disclosed |
| EP-2190873-A1 | TRUNCATED GLP-1 DERIVATIVES AND THEIR THERAPEUTICAL USE | Novo Nordisk A/S (DK) | 2010-06-02 | — | — | EP | disclosed |
| EP-2190872-A1 | GLUCAGON-LIKE PEPTIDE-1 DERIVATIVES AND THEIR PHARMACEUTICAL USE | Novo Nordisk A/S (DK) | 2010-06-02 | — | — | EP | disclosed |
| EP-2190460-A1 | PEPTIDES DERIVATIZED WITH A-B-C-D- AND THEIR THERAPEUTICAL USE | Novo Nordisk A/S (DK) | 2010-06-02 | — | — | EP | disclosed |
| EP-2183279-A1 | METHOD FOR SELECTIVELY MODIFYING A PROTEIN | Novo Nordisk A/S (DK) | 2010-05-12 | — | — | EP | disclosed |
| WO-2010046357-A1 | AMYLIN DERIVATIVES | NOVO NORDISK A/S (DK) | 2010-04-29 | — | — | WO | disclosed |
| WO-2010036961-A1 | SPINAL CORD INJURY, INFLAMMATION, AND IMMUNE-DISEASE: LOCAL CONTROLLED RELEASE OF THERAPEUTIC AGENTS | INVIVO THERAPEUTICS CORPORATION (US) | 2010-04-01 | — | — | WO | disclosed |
| EP-2167059-A2 | NOVEL PROLACTIN COMPOUNDS | Novo Nordisk A/S (DK) | 2010-03-31 | — | — | EP | disclosed |
| EP-2167116-A2 | PEPTIDES WITH HIGH AFFINITY FOR THE PROLACTIN RECEPTOR | Novo Nordisk A/S (DK) | 2010-03-31 | — | — | EP | disclosed |
| EP-1704165-B1 | GLP-1 COMPOUNDS | NOVO NORDISK AS (DK) | 2010-03-17 | — | — | EP | disclosed |
| US-20100056764-A1 | Antibodies against human NKG2D and uses thereof | NOVO NORDISK A/S (DK) | 2010-03-04 | — | — | US | disclosed |
| US-20100056433-A1 | Novel Peptides for Use in the Treatment of Obesity | NOVO NORDISK A/S (DK) | 2010-03-04 | — | — | US | disclosed |
| US-20100056428-A1 | MODIFIED PROTEINS | NOVO NORDISK HEALTH CARE AG (CH) | 2010-03-04 | — | — | US | disclosed |
| WO-2010015668-A1 | CONJUGATED PROTEINS WITH PROLONGED IN VIVO EFFICACY | NOVO NORDISK A/S (DK) | 2010-02-11 | — | — | WO | disclosed |
| US-20100036000-A1 | CONTROLLED RELEASE ANTIMICROBIAL COMPOSITIONS AND METHODS FOR THE TREATMENT OF OTIC DISORDERS | OTONOMY, INC. (US) | 2010-02-11 | — | — | US | disclosed |
| US-20100029903-A1 | Polypeptide Protracting Tags | NOVO NORDISK A/S (DK) | 2010-02-04 | — | — | US | disclosed |
| US-20100022661-A1 | CONTROLLED RELEASE COMPOSITIONS FOR MODULATING FREE-RADICAL INDUCED DAMAGE AND METHODS OF USE THEREOF | OTONOMY, INC. (US) | 2010-01-28 | — | — | US | disclosed |
| US-20100022454-A1 | Peptides with High Affinity for the Prolactin Receptor | NOVO NORDISK A/S (DK) | 2010-01-28 | — | — | US | disclosed |
| US-20100021416-A1 | CONTROLLED-RELEASE OTIC STRUCTURE MODULATING AND INNATE IMMUNE SYSTEM MODULATING COMPOSITIONS AND METHODS FOR THE TREATMENT OF OTIC DISORDERS | OTONOMY, INC. (US) | 2010-01-28 | — | — | US | disclosed |
| WO-2010011605-A2 | CONTROLLED-RELEASE OTIC STRUCTURE MODULATING AND INNATE IMMUNE SYSTEM MODULATING COMPOSITIONS AND METHODS FOR THE TREATMENT OF OTIC DISORDERS | OTONOMY, INC. (US) | 2010-01-28 | — | — | WO | disclosed |
| US-20100015146-A1 | TREATING DIABETES USING INHIBITORS OF IL-1 | NOVO NORDISK A/S (DK) | 2010-01-21 | — | — | US | disclosed |
| US-20100016238-A1 | Peptides for Use in the Treatment of Obesity | NOVO NORDISK A/S (DK) | 2010-01-21 | — | — | US | disclosed |
| US-20100016237-A1 | Novel Peptides for Use in the Treatment of Obesity | NOVO NORDISK A/S (DK) | 2010-01-21 | — | — | US | disclosed |
| US-20100009917-A1 | Modulating Enzymatic Processes by Addition of Diolcontaining Substances | NOVO NORDISK HEALTH CARE AG (CH) | 2010-01-14 | — | — | US | disclosed |
| WO-2009156473-A1 | DERIVATISED HYBRID PEPTIDES OF AMYLIN AND SALMON CALCITONIN | NOVO NORDISK A/S (DK) | 2009-12-30 | — | — | WO | disclosed |
| CN-101617053-A | The method that contains the material regulatory enzyme of glycol by interpolation | NOVO NORDISK HEALTHCARE AG | 2009-12-30 | — | — | CN | disclosed |
| US-20090318353-A1 | Acylated Exendin-4 Compounds | NOVO NORDISK A/S (DK) | 2009-12-24 | — | — | US | disclosed |
| US-20090304706-A1 | ANTAGONIST ANTI-CD40 ANTIBODY PHARMACEUTICAL COMPOSITIONS | NOVARTIS AG (CH) | 2009-12-10 | — | — | US | disclosed |
| US-20090306225-A1 | AURIS FORMULATIONS FOR TREATING OTIC DISEASES AND CONDITIONS | OTONOMY, INC. (US) | 2009-12-10 | — | — | US | disclosed |
| US-20090297533-A1 | CONTROLLED RELEASE IMMUNOMODULATOR COMPOSITIONS AND METHODS FOR THE TREATMENT OF OTIC DISORDERS | OTONOMY, INC. (US) | 2009-12-03 | — | — | US | disclosed |
| WO-2009138511-A1 | LONG-ACTING Y2 AND/OR Y4 RECEPTOR AGONISTS | NOVO NORDISK A/S (DK) | 2009-11-19 | — | — | WO | disclosed |
| US-20090269843-A1 | Hemopexin fusion proteins | NOVO NORDISK A/S (DK) | 2009-10-29 | — | — | US | disclosed |
| WO-2009130198-A2 | HYPERGLYCOSYLATED HUMAN COAGULATION FACTOR IX | NOVO NORDISK A/S (DK) | 2009-10-29 | — | — | WO | disclosed |
| US-20090264366-A1 | Transglutaminase Mediated Conjugation of Peptides | NOVO NORDISK HEALTHCARE AG (CH) | 2009-10-22 | — | — | US | disclosed |
| US-20090253166-A1 | Conjugation of Peptides | NOVO NORDISK A/S (DK) | 2009-10-08 | — | — | US | disclosed |
| US-20090253864-A1 | IL-21 Derivatives and Variants | NOVO NORDISK A/S (DK) | 2009-10-08 | — | — | US | disclosed |
| US-20090252720-A1 | Prolonged FIX Analogues and Derivatives | NOVO NORDISK HEALTH CARE AG (CH) | 2009-10-08 | — | — | US | disclosed |
| EP-2106406-A2 | NOVEL PEPTIDES FOR USE IN THE TREATMENT OF OBESITY | Novo Nordisk A/S (DK) | 2009-10-07 | — | — | EP | disclosed |
| EP-2106405-A2 | PEPTIDES FOR USE IN THE TREATMENT OF OBESITY | Novo Nordisk A/S (DK) | 2009-10-07 | — | — | EP | disclosed |
| EP-2106407-A2 | NOVEL PEPTIDES FOR USE IN THE TREATMENT OF OBESITY | Novo Nordisk A/S (DK) | 2009-10-07 | — | — | EP | disclosed |
| EP-2104684-A1 | PEPTIDES FOR USE IN THE TREATMENT OF OBESITY | Novo Nordisk A/S (DK) | 2009-09-30 | — | — | EP | disclosed |
| US-20090240028-A1 | Synthesis and Application of New Structural Well Defined Branched Polymers as Conjugating Agents for Peptides | NOVO NORDISK A/S (DK) | 2009-09-24 | — | — | US | disclosed |
| US-20090203581-A1 | Novel Peptides for Use in the Treatment of Obesity | NOVO NORDISK A/S (DK) | 2009-08-13 | — | — | US | disclosed |
| EP-2087905-A2 | Interleukin-20 for treating and diagnosing conditions associated with neovascularisation | NOVO NORDISK A/S (DK) | 2009-08-12 | — | — | EP | disclosed |
| WO-2009092805-A1 | HUMANIZED ANTI-HUMAN NKG2A MONOCLONAL ANTIBODY | NOVO NORDISK A/S (DK) | 2009-07-30 | — | — | WO | disclosed |
| US-20090176967-A1 | Conjugation of FVII | NOVO NORDISK HEALTHCARE A/G (CH) | 2009-07-09 | — | — | US | disclosed |
| EP-2076534-A1 | PEPTIDES WITH HIGH AFFINITY FOR THE PROLACTIN RECEPTOR | NOVO NORDISK A/S (DK) | 2009-07-08 | — | — | EP | disclosed |
| WO-2009077483-A1 | ANTIBODIES AGAINST HUMAN NKG2D AND USES THEREOF | NOVO NORDISK A/S (DK) | 2009-06-25 | — | — | WO | disclosed |
| US-20090156478-A1 | Acylated GLP-1 Compounds | NOVO NORDISK A/S (DK) | 2009-06-18 | — | — | US | disclosed |
| WO-2009063069-A2 | ENDOTOXIN REMOVAL | NOVO NORDISK A/S (DK) | 2009-05-22 | — | — | WO | disclosed |
| EP-2057189-A1 | ACYLATED EXENDIN-4 COMPOUNDS | NOVO NORDISK A/S (DK) | 2009-05-13 | — | — | EP | disclosed |
| US-20090111730-A1 | Polypeptide protracting tags | NOVO NORDISK A/S (DK) | 2009-04-30 | — | — | US | disclosed |
| US-7524813-B2 | Selectively conjugated peptides and methods of making the same | NOVO NORDISK HEALTH CARE AG (CH) | 2009-04-28 | — | — | US | disclosed |
| US-20090105134-A1 | C-Terminally Pegylated Growth Hormones | NOVO NORDISK A/S (DK) | 2009-04-23 | — | — | US | disclosed |
| US-20090099085-A1 | Amylin Derivatives | NOVO NORDISK A/S (DK) | 2009-04-16 | — | — | US | disclosed |
| WO-2009043940-A2 | PEPTIDES WITH HIGH AFFINITY FOR THE PROLACTIN RECEPTOR | NOVO NORDISK A/S (DK) | 2009-04-09 | — | — | WO | disclosed |
| EP-2040757-A2 | NEW PROTEIN CONJUGATES AND METHODS FOR THEIR PREPARATION | Novo Nordisk Health Care AG (CH) | 2009-04-01 | — | — | EP | disclosed |
| US-20090081240-A1 | Human Anti-Kir Antibodies | NOVO NORDISK A/S (DK) | 2009-03-26 | — | — | US | disclosed |
| EP-2038306-A1 | ANTI-NKG2A ANTIBODIES AND USES THEREOF | Novo Nordisk A/S (DK) | 2009-03-25 | — | — | EP | disclosed |
| WO-2009034119-A1 | IMPROVED DERIVATIVES OF AMYLIN | NOVO NORDISK A/S (DK) | 2009-03-19 | — | — | WO | disclosed |
| US-20090075340-A1 | Kir-Binding Agents and Methods of Use Thereof | NOVO NORDISK A/S (DK) | 2009-03-19 | — | — | US | disclosed |
| EP-2036923-A1 | Improved derivates of amylin | NOVO NORDISK A/S (DK) | 2009-03-18 | — | — | EP | disclosed |
| WO-2009030738-A1 | GLUCAGON-LIKE PEPTIDE-1 DERIVATIVES AND THEIR PHARMACEUTICAL USE | NOVO NORDISK A/S (DK) | 2009-03-12 | — | — | WO | disclosed |
| WO-2009030771-A1 | PEPTIDES DERIVATIZED WITH A-B-C-D- AND THEIR THERAPEUTICAL USE | NOVO NORDISK A/S (DK) | 2009-03-12 | — | — | WO | disclosed |
| WO-2009030774-A1 | TRUNCATED GLP-1 DERIVATIVES AND THEIR THERAPEUTICAL USE | NOVO NORDISK A/S (DK) | 2009-03-12 | — | — | WO | disclosed |
| EP-2033662-A1 | Transglutaminase mediated conjugation of peptides | Novo Nordisk Health Care AG (CH) | 2009-03-11 | — | — | EP | disclosed |
| US-20090060861-A1 | Stabilized Polypeptide Formulations | NOVO NORDISK A/S (DK) | 2009-03-05 | — | — | US | disclosed |
| US-20090062192-A1 | Dimeric Peptide Agonists of the Glp-1 Receptor | NOVO NORDISK A/S (DK) | 2009-03-05 | — | — | US | disclosed |
| WO-2009027369-A1 | METHOD FOR SELECTIVELY MODIFYING A PROTEIN | NOVO NORDISK A/S (DK) | 2009-03-05 | — | — | WO | disclosed |
| EP-2029738-A2 | FACTOR IX ANALOGUES HAVING PROLONGED IN VIVO HALF LIFE | Novo Nordisk Health Care AG (CH) | 2009-03-04 | — | — | EP | disclosed |
| US-20090042781-A1 | Methods for Treating Diabetes | NOVO NORDISK A/S (DK) | 2009-02-12 | — | — | US | disclosed |
| US-20090035254-A1 | IL-21 Variants | NOVO NORDISK A/S (DK) | 2009-02-05 | — | — | US | disclosed |
| EP-2019841-A2 | ANTAGONIST ANTI-CD40 ANTIBODY PHARMACEUTICAL COMPOSITIONS | Novartis AG (CH) | 2009-02-04 | — | — | EP | disclosed |
| WO-2009004058-A2 | NOVEL PROLACTIN COMPOUNDS | NOVO NORDISK A/S (DK) | 2009-01-08 | — | — | WO | disclosed |
| US-20090010843-A1 | Methods of Identifying Antibodies to Ligands of Orphan Receptors | NOVO NORDISK A/S (DK) | 2009-01-08 | — | — | US | disclosed |
| WO-2009003732-A2 | PEPTIDES WITH HIGH AFFINITY FOR THE PROLACTIN RECEPTOR | NOVO NORDISK A/S (DK) | 2009-01-08 | — | — | WO | disclosed |
| US-20090005312-A1 | NOVEL GLP-1 ANALOGUES LINKED TO ALBUMIN-LIKE AGENTS | NOVO NORDISK A/S (DK) | 2009-01-01 | — | — | US | disclosed |
| EP-2004213-A1 | GLP-1 PEPTIDE AGONISTS | Novo Nordisk A/S (DK) | 2008-12-24 | — | — | EP | disclosed |
| US-20080306008-A1 | Peptides for Use in the Treatment of Obesity | NOVA NORDISK A/S (DK) | 2008-12-11 | — | — | US | disclosed |
| US-20080305986-A1 | Multimers of Peptides | CONDE FIEBOES KILLIAN WALDEMAR | 2008-12-11 | — | — | US | disclosed |
| US-20080305117-A1 | Kir-Binding Agents and Methods of Use Thereof | NOVO NORDISK A/S/ (DK) | 2008-12-11 | — | — | US | disclosed |
| EP-1996617-A2 | AMYLIN DERIVATIVES | Novo Nordisk A/S (DK) | 2008-12-03 | — | — | EP | disclosed |
| US-20080280820-A1 | Novel Peptides for Use in the Treatment of Obesity | NOVO NORDISK A/S (DK) | 2008-11-13 | — | — | US | disclosed |
| US-20080274547-A1 | USE OF NITRIC OXIDE MODULATORS IN AGROBACTERIUM-MEDIATED PLANT TRANSFORMATION | MONSANTO TECHNOLOGY LLC | 2008-11-06 | — | — | US | disclosed |
| US-20080274075-A1 | Poly(Ethylene Glycol) Derivatives and Process For Their Coupling to Proteins | NOVO NORDISK HEALTHCARE A/G (CH) | 2008-11-06 | — | — | US | disclosed |
| US-20080267907-A1 | Stabilized Polypeptide Formulations | NOVO NORDISK A/S (DK) | 2008-10-30 | — | — | US | disclosed |
| US-20080249007-A1 | Protracted Exendin-4 Compounds | NOVO NORDISK A/S (DK) | 2008-10-09 | — | — | US | disclosed |
| US-20080227691-A1 | Blood Coagulation FVIII Analogues | NOVO NORDISK HEALTH CARE AG (CH) | 2008-09-18 | — | — | US | disclosed |
| EP-1963343-A1 | POLYPEPTIDE PROTRACTING TAGS | Novo Nordisk A/S (DK) | 2008-09-03 | — | — | EP | disclosed |
| US-20080206192-A1 | Treating cell proliferative disorders via administration of mixture comprising interleukin-21 and anti-cancer monoclonal antibody (Alemtuzumab) | NOVO NORDISK A/S (DK) | 2008-08-28 | — | — | US | disclosed |
| US-20080207493-A1 | Compounds for Use in the Treatment of Obesity | NOVO NORDISK A/S (DK) | 2008-08-28 | — | — | US | disclosed |
| US-20080207507-A1 | Extended Glp-1 Compounds | NOVO NORDISK A/S (DK) | 2008-08-28 | — | — | US | disclosed |
| US-20080182785-A1 | Protracted Glp-1 Compounds | NOVO NORDISK A/S (DK) | 2008-07-31 | — | — | US | disclosed |
| US-20080182783-A1 | Growth Hormone Conjugates | NOVO NORDISK A/S (DK) | 2008-07-31 | — | — | US | disclosed |
| WO-2008087186-A2 | PEPTIDES FOR USE IN THE TREATMENT OF OBESITY | NOVO NORDISK A/S (DK) | 2008-07-24 | — | — | WO | disclosed |
| WO-2008087189-A2 | PEPTIDES FOR USE IN THE TREATMENT OF OBESITY | NOVO NORDISK A/S (DK) | 2008-07-24 | — | — | WO | disclosed |
| WO-2008087188-A2 | PEPTIDES FOR USE IN THE TREATMENT OF OBESITY | NOVO NORDISK A/S (DK) | 2008-07-24 | — | — | WO | disclosed |
| WO-2008087187-A1 | PEPTIDES FOR USE IN THE TREATMENT OF OBESITY | NOVO NORDISK A/S (DK) | 2008-07-24 | — | — | WO | disclosed |
| US-20080176789-A1 | Purification of Factor Xlll Polypeptides From Biological Materials | NOVC NORDISK HEALTHCARE A/G (CH) | 2008-07-24 | — | — | US | disclosed |
| US-7388126-B2 | Such as NG-monomethyl-L-arginine, monoacetate salt; corn plants | MONSANTO TECHNOLOGY LLC (US) | 2008-06-17 | — | — | US | disclosed |
| EP-1929302-A2 | METHODS OF IDENTIFYING ANTIBODIES TO LIGANDS OF ORPHAN RECEPTORS | Novo Nordisk A/S (DK) | 2008-06-11 | — | — | EP | disclosed |
| US-20080108557-A1 | Modified Proteins | NOVO NORDISK HEALTHCARE A/G (CH) | 2008-05-08 | — | — | US | disclosed |
| WO-2008040758-A1 | PEPTIDES WITH HIGH AFFINITY FOR THE PROLACTIN RECEPTOR | NOVO NORDISK A/S (DK) | 2008-04-10 | — | — | WO | disclosed |
| EP-1906991-A2 | USE OF GLP-1 RECEPTOR AGONISTS AND/OR DPP-IV INHIBITORS IN COMBINATION WITH PROTON PUMP INHIBITORS AND PPAR AGONISTS FOR THE PREPARATION OF A MEDICAMENT FOR THE TREATMENT OF DIABETES TYPE I, DIABETES TYPE II AND IMPAIRED PANCREATIC BETA-CELL FUNCTION | Novo Nordisk A/S (DK) | 2008-04-09 | — | — | EP | disclosed |
| EP-1907010-A2 | PEPTIDES FOR USE IN THE TREATMENT OF OBESITY | Novo Nordisk A/S (DK) | 2008-04-09 | — | — | EP | disclosed |
| WO-2008028684-A2 | PEPTIDES WITH HIGH AFFINITY FOR THE PROLACTIN RECEPTOR | NOVO NORDISK A/S (DK) | 2008-03-13 | — | — | WO | disclosed |
| US-20080064630-A1 | Osteogenic Growth Peptide Fusion Proteins | NOVO NORDISK A/S (DK) | 2008-03-13 | — | — | US | disclosed |
| WO-2008023050-A1 | ACYLATED EXENDIN-4 COMPOUNDS | NOVO NORDISK A/S (DK) | 2008-02-28 | — | — | WO | disclosed |
| EP-1889070-A1 | METHOD FOR DETERMINING THE CONCENTRATION OF ASYMMETRIC DIMETHYLARGININE (ADMA) | Medizinische Fakultät (DE) | 2008-02-20 | — | — | EP | disclosed |
| EP-1888117-A1 | STABILIZED POLYPEPTIDE FORMULATIONS | Novo Nordisk A/S (DK) | 2008-02-20 | — | — | EP | disclosed |
| EP-1888118-A1 | STABILIZED POLYPEPTIDE FORMULATIONS | NOVO NORDISK A/S (DK) | 2008-02-20 | — | — | EP | disclosed |
| US-20080039387-A1 | Novel Peptides for Use in the Treatment of Obesity | NOVO NORDISK A/S (DK) | 2008-02-14 | — | — | US | disclosed |
| EP-1289507-B1 | USE OF AN ALDOSTERONE ANTAGONIST FOR THE TREATMENT OR PROPHYLAXIS OF ALDOSTERONE-MEDIATED PATHOGENIC EFFECTS | PHARMACIA CORP (US) | 2008-02-13 | — | — | EP | disclosed |
| EP-1885768-A1 | NEW POLY(ETHYLENE GLYCOL) DERIVATIVES AND PROCESS FOR THEIR COUPLING TO PROTEINS | Novo Nordisk Health Care AG (CH) | 2008-02-13 | — | — | EP | disclosed |
| WO-2008009545-A1 | ANTI-NKG2A ANTIBODIES AND USES THEREOF | NOVO NORDISK A/S (DK) | 2008-01-24 | — | — | WO | disclosed |
| EP-1877439-A2 | IL-21 VARIANTS | Novo Nordisk A/S (DK) | 2008-01-16 | — | — | EP | disclosed |
| WO-2008003750-A2 | NEW PROTEIN CONJUGATES AND METHODS FOR THEIR PREPARATION | NOVO NORDISK HEALTH CARE AG (DK) | 2008-01-10 | — | — | WO | disclosed |
| WO-2008003748-A2 | CD300LG POLYPEPTIDES AND THEIR USE IN TREATING AUTOIMMUNE DISEASES | NOVO NORDISK A/S (DK) | 2008-01-10 | — | — | WO | disclosed |
| EP-1871801-A2 | BLOOD COAGULATION FVIII ANALOGUES | Novo Nordisk Health Care AG (CH) | 2008-01-02 | — | — | EP | disclosed |
| US-20070292391-A1 | Stabilized Interferon Liquid Formulations | ARES TRADING S.A. (CH) | 2007-12-20 | — | — | US | disclosed |
| EP-1863521-A1 | EXTENDED GLP-1 COMPOUNDS | Novo Nordisk A/S (DK) | 2007-12-12 | — | — | EP | disclosed |
| EP-1863839-A2 | ACYLATED GLP-1 COMPOUNDS | NOVO NORDISK A/S (DK) | 2007-12-12 | — | — | EP | disclosed |
| EP-1863841-A1 | COMPOUNDS FOR USE IN THE TREATMENT OF OBESITY | Novo Nordisk A/S (DK) | 2007-12-12 | — | — | EP | disclosed |
| EP-1863537-A2 | DIMERIC PEPTIDE AGONISTS OF THE GLP-1 RECEPTOR | Novo Nordisk A/S (DK) | 2007-12-12 | — | — | EP | disclosed |
| WO-2007135182-A2 | FACTOR IX ANALOGUES HAVING PROLONGED IN VIVO HALF LIFE | NOVO NORDISK HEALTH CARE AG (DK) | 2007-11-29 | — | — | WO | disclosed |
| EP-1853321-A2 | INSULINOTROPIC AGENTS CONJUGATED WITH STRUCTURALLY WELL DEFINED BRANCHED POLYMERS | NOVO NORDISK A/S (DK) | 2007-11-14 | — | — | EP | disclosed |
| WO-2007124299-A2 | ANTAGONIST ANTI-CD40 ANTIBODY PHARMACEUTICAL COMPOSITIONS | NOVARTIS AG (CH) | 2007-11-01 | — | — | WO | disclosed |
| US-20070244299-A1 | Method of Stabilizing Proteins | ARES TRADING S.A. (CH) | 2007-10-18 | — | — | US | disclosed |
| WO-2007113205-A1 | GLP-1 PEPTIDE AGONISTS | NOVO NORDISK A/S (DK) | 2007-10-11 | — | — | WO | disclosed |
| EP-1836225-A1 | KIR-BINDING AGENTS AND METHODS OF USE THEREOF | NOVO NORDISK A/S (DK) | 2007-09-26 | — | — | EP | disclosed |
| WO-2007104789-A2 | AMYLIN DERIVATIVES | NOVO NORDISK A/S (DK) | 2007-09-20 | — | — | WO | disclosed |
| US-20070203058-A1 | Novel Glp-1 Derivatives | NOVO NORDISK A/S (DK) | 2007-08-30 | — | — | US | disclosed |
| US-20070191324-A1 | Methods for treatment or prophylaxis of aldosterone-mediated pathogenic effects in a subject using an epoxy-steroidal aldosterone antagonist | WILLIAMS GORDON H | 2007-08-16 | — | — | US | disclosed |
| EP-1812471-A2 | PEPTIDES FOR USE IN TREATING OF OBESITY | Novo Nordisk A/S (DK) | 2007-08-01 | — | — | EP | disclosed |
| EP-1809665-A2 | MC4R SELECTIVE PEPTIDES AND THEIR USE IN THE TREATMENT OF OBESITY | NOVO NORDISK A/S (DK) | 2007-07-25 | — | — | EP | disclosed |
| EP-1809666-A2 | PEPTIDES FOR USE IN THE TREATING OBESITY | Novo Nordisk A/S (DK) | 2007-07-25 | — | — | EP | disclosed |
| EP-1809667-A1 | PEPTIDES FOR USE IN THE TREATMENT OF OBESITY | NOVO NORDISK A/S (DK) | 2007-07-25 | — | — | EP | disclosed |
| CN-1997670-A | Human anti-KIR antibodies | NOVO NORDISK AS (DK) | 2007-07-11 | — | — | CN | disclosed |
| EP-1799710-A2 | PROTRACTED GLP-1 COMPOUNDS | NOVO NORDISK A/S (DK) | 2007-06-27 | — | — | EP | disclosed |
| EP-1799711-A2 | PROTRACTED EXENDIN-4 COMPOUNDS | NOVO NORDISK A/S (DK) | 2007-06-27 | — | — | EP | disclosed |
| WO-2007068718-A1 | POLYPEPTIDE PROTRACTING TAGS | NOVO NORDISK A/S (DK) | 2007-06-21 | — | — | WO | disclosed |
| EP-1791868-A2 | ANTIBODIES BINDING TO RECEPTORS KIR2DL1, -2, 3 BUT NOT KIR2DS4 AND THEIR THERAPEUTIC USE | NOVO NORDISK A/S (DK) | 2007-06-06 | — | — | EP | disclosed |
| US-20070110809-A1 | Stabilised compositions | GLAXOSMITHKLINE BIOLOGICALS SA (BE) | 2007-05-17 | — | — | US | disclosed |
| US-20070111926-A1 | Conjugation of peptides | NOVO NORDISK A/S (DK) | 2007-05-17 | — | — | US | disclosed |
| EP-1784415-A2 | PURIFICATION OF FACTOR XIII POLYPEPTIDES FROM BIOLOGICAL MATERIALS | Novo Nordisk Health Care AG (CH) | 2007-05-16 | — | — | EP | disclosed |
| US-20070105750-A1 | Novel plasma protein affinity tags | NOVO NORDISK A/S (DK) | 2007-05-10 | — | — | US | disclosed |
| US-20070105770-A1 | Transglutaminase mediated conjugation of peptides | NOVO NORDISK A/S (DK) | 2007-05-10 | — | — | US | disclosed |
| EP-1781699-A1 | MULTIMERS OF PEPTIDES | NOVO NORDISK A/S (DK) | 2007-05-09 | — | — | EP | disclosed |
| EP-1781791-A2 | HEMOPEXIN FUSION PROTEINS | NOVO NORDISK A/S (DK) | 2007-05-09 | — | — | EP | disclosed |
| EP-1778838-A2 | CONJUGATION OF FVII | Novo Nordisk Health Care AG (CH) | 2007-05-02 | — | — | EP | disclosed |
| US-20070093417-A1 | Novel GLP-1 analogues linked to albumin-like agents | NOVO NORDISK A/S (DK) | 2007-04-26 | — | — | US | disclosed |
| WO-2007039507-A2 | METHODS OF IDENTIFYING ANTIBODIES TO LIGANDS OF ORPHAN RECEPTORS | NOVO NORDISK A/S (DK) | 2007-04-12 | — | — | WO | disclosed |
| EP-1765408-A2 | POLYPEPTIDE PROTRACTING TAGS COMPRISING A TETRAZOLE MOIETY | NOVO NORDISK A/S (DK) | 2007-03-28 | — | — | EP | disclosed |
| US-20070042956-A1 | Novel GLP-1 compounds | NOVO NORDISK A/S (DK) | 2007-02-22 | — | — | US | disclosed |
| CN-1918177-A | Novel glp-1 compounds | NOVO NORDISK AS (DK) | 2007-02-21 | — | — | CN | disclosed |
| EP-1750750-A1 | METHOD OF STABILIZING PROTEINS | Ares Trading S.A. (CH) | 2007-02-14 | — | — | EP | disclosed |
| US-20070031374-A1 | Treating cell proliferative disorders via administration of mixture comprising interleukin-21 and anti-cancer monoclonal antibody | NOVO NORDISK A/S (DK) | 2007-02-08 | — | — | US | disclosed |
| WO-2007009894-A2 | PEPTIDES FOR USE IN THE TREATMENT OF OBESITY | NOVO NORDISK A/S (DK) | 2007-01-25 | — | — | WO | disclosed |
| EP-1740701-A1 | OSTEOGENIC GROWTH PEPTIDE FUSION PROTEINS | NOVO NORDISK A/S (DK) | 2007-01-10 | — | — | EP | disclosed |
| CN-1882357-A | Therapeutic use of factor XI | NOVO NORDISK HEALTHCARE AG (CH) | 2006-12-20 | — | — | CN | disclosed |
| WO-2006128497-A1 | PHARMACEUTICAL FORMULATION OF FACTOR XI | NOVO NORDISK A/S (DK) | 2006-12-07 | — | — | WO | disclosed |
| WO-2006128419-A1 | METHOD FOR DETERMINING THE CONCENTRATION OF ASYMMETRIC DIMETHYLARGININE (ADMA) | MEDIZINISCHE FAKULTÄT (DE) | 2006-12-07 | — | — | WO | disclosed |
| WO-2006125762-A1 | STABILIZED POLYPEPTIDE FORMULATIONS | NOVO NORDISK A/S (DK) | 2006-11-30 | — | — | WO | disclosed |
| WO-2006125763-A1 | STABILIZED POLYPEPTIDE FORMULATIONS | NOVO NORDISK A/S (DK) | 2006-11-30 | — | — | WO | disclosed |
| WO-2006122982-A1 | NEW POLY(ETHYLENE GLYCOL) DERIVATIVES AND PROCESS FOR THEIR COUPLING TO PROTEINS | NOVO NORDISK HEALTH CARE AG (DK) | 2006-11-23 | — | — | WO | disclosed |
| WO-2006111524-A2 | IL-21 VARIANTS | NOVO NORDISK A/S (DK) | 2006-10-26 | — | — | WO | disclosed |
| US-20060228331-A1 | IL-21 Derivatives and variants | NOVO NORDISK A/S (DK) | 2006-10-12 | — | — | US | disclosed |
| WO-2006103298-A2 | BLOOD COAGULATION FVIII ANALOGUES | NOVO NORDISK HEALTH CARE AG (DK) | 2006-10-05 | — | — | WO | disclosed |
| EP-1704165-A1 | NOVEL GLP-1 COMPOUNDS | NOVO NORDISK A/S (DK) | 2006-09-27 | — | — | EP | disclosed |
| WO-2006097536-A2 | DIMERIC PEPTIDE AGONISTS OF THE GLP-1 RECEPTOR | NOVO NORDISK A/S (DK) | 2006-09-21 | — | — | WO | disclosed |
| WO-2006097537-A2 | ACYLATED GLP-1 COMPOUNDS | NOVO NORDISK A/S (DK) | 2006-09-21 | — | — | WO | disclosed |
| WO-2006097538-A1 | EXTENDED GLP-1 COMPOUNDS | NOVO NORDISK A/S (DK) | 2006-09-21 | — | — | WO | disclosed |
| WO-2006097535-A2 | PEPTIDE AGONISTS OF THE GLUCAGON FAMILY WITH SECRETIN LIKE ACTIVITY | NOVO NORDISK A/S (DK) | 2006-09-21 | — | — | WO | disclosed |
| WO-2006097526-A1 | COMPOUNDS FOR USE IN THE TREATMENT OF OBESITY | NOVO NORDISK A/S (DK) | 2006-09-21 | — | — | WO | disclosed |
| EP-1696962-A2 | NOVEL GLP-1 ANALOGUES LINKED TO ALBUMIN-LIKE AGENTS | NOVO NORDISK A/S (DK) | 2006-09-06 | — | — | EP | disclosed |
| WO-2006087354-A2 | INSULINOTROPIC AGENTS CONJUGATED WITH STRUCTURALLY WELL DEFINED BRANCHED POLYMERS | NOVO NORDISK A/S (DK) | 2006-08-24 | — | — | WO | disclosed |
| US-20060188476-A1 | Interleukin 20 (IL-20) and its use in neovascularisation | NOVO NORDISK A/S (DK) | 2006-08-24 | — | — | US | disclosed |
| US-20060182714-A1 | Synthesis and application of new structural well defined branched polymers as conjugating agents for peptides | NOVO NORDISK A/S (DK) | 2006-08-17 | — | — | US | disclosed |
| EP-1687020-A1 | THERAPEUTIC USE OF FACTOR XI | Novo Nordisk Health Care AG (CH) | 2006-08-09 | — | — | EP | disclosed |
| US-7087633-B2 | Method for treating perinatal asphyxia in a human or animal neonate | UNIVERSITAIR MEDISCH CENTRUM (NL) | 2006-08-08 | — | — | US | disclosed |
| EP-1680138-A1 | COMBINATION THERAPY | NOVO NORDISK A/S (DK) | 2006-07-19 | — | — | EP | disclosed |
| WO-2006072626-A1 | KIR-BINDING AGENTS AND METHODS OF USE THEREOF | NOVO NORDISK A/S (DK) | 2006-07-13 | — | — | WO | disclosed |
| EP-1675869-A2 | STABILISED COMPOSITIONS | CHIRON CORPORATION (US) | 2006-07-05 | — | — | EP | disclosed |
| EP-1673387-A1 | IL-21 DERIVATIVES | NOVO NORDISK A/S (DK) | 2006-06-28 | — | — | EP | disclosed |
| EP-1670515-A2 | ALBUMIN-BINDING DERIVATIVES OF THERAPEUTIC PEPTIDES | NOVO NORDISK A/S (DK) | 2006-06-21 | — | — | EP | disclosed |
| EP-1667724-A2 | ALBUMIN-BINDING DERIVATIVES OF THERAPEUTIC PEPTIDES | NOVO NORDISK A/S (DK) | 2006-06-14 | — | — | EP | disclosed |
| EP-1094849-B1 | METHODS FOR INCREASING VASCULARIZATION AND PROMOTING WOUND HEALING | ENCELLE INC (US) | 2006-05-17 | — | — | EP | disclosed |
| US-20060100280-A1 | Cell growth regulator | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2006-05-11 | — | — | US | disclosed |
| WO-2006048452-A2 | PEPTIDES FOR USE IN TREATING OF OBESITY | NOVO NORDISK A/S (DK) | 2006-05-11 | — | — | WO | disclosed |
| WO-2006048449-A2 | MC4R SELECTIVE PEPTIDES AND THEIR USE IN THE TREATMENT OF OBESITY | NOVO NORDISK A/S (DK) | 2006-05-11 | — | — | WO | disclosed |
| WO-2006048450-A2 | PEPTIDES FOR USE IN THE TREATING OBESITY | NOVO NORDISK A/S (DK) | 2006-05-11 | — | — | WO | disclosed |
| WO-2006048451-A1 | PEPTIDES FOR USE IN THE TREATMENT OF OBESITY | NOVO NORDISK A/S (DK) | 2006-05-11 | — | — | WO | disclosed |
| EP-1653995-A1 | INTERLEUKIN-20 FOR TREATING AND DIAGNOSING CONDITIONS ASSOCIATED WITH NEOVASCULARISATION | NOVO NORDISK A/S (DK) | 2006-05-10 | — | — | EP | disclosed |
| EP-1654004-A2 | SYNTHESIS AND APPLICATION OF NEW STRUCTURAL WELL DEFINED BRANCHED POLYMERS AS CONJUGATING AGENTS FOR PEPTIDES | NOVO NORDISK A/S (DK) | 2006-05-10 | — | — | EP | disclosed |
| US-20060093576-A1 | Stabilized liquid polypeptide-containing pharmaceutical compositions | CHIRON CORPORATION (US) | 2006-05-04 | — | — | US | disclosed |
| US-20060093598-A1 | Stabilized liquid polypeptide-containing pharmaceutical compositions | CHIRON CORPORATION (US) | 2006-05-04 | — | — | US | disclosed |
| US-7030086-B2 | Stabilized liquid polypeptide-containing pharmaceutical compositions | CHIRON CORPORATION (US) | 2006-04-18 | — | — | US | disclosed |
| WO-2006037810-A2 | PROTRACTED GLP-1 COMPOUNDS | NOVO NORDISK A/S (DK) | 2006-04-13 | — | — | WO | disclosed |
| WO-2006037811-A2 | PROTRACTED EXENDIN-4 COMPOUNDS | NOVO NORDISK A/S (DK) | 2006-04-13 | — | — | WO | disclosed |
| EP-1321516-B1 | Hydrogel matrix for cellular tissue storage | ENCELLE INC (US) | 2006-03-22 | — | — | EP | disclosed |
| WO-2006021584-A2 | PURIFICATION OF FACTOR XIII POLYPEPTIDES FROM BIOLOGICAL MATERIALS | NOVO NORDISK HEALTH CARE AG (CH) | 2006-03-02 | — | — | WO | disclosed |
| WO-2006018428-A2 | HEMOPEXIN FUSION PROTEINS | NOVO NORDISK A/S (DK) | 2006-02-23 | — | — | WO | disclosed |
| WO-2006018429-A1 | MULTIMERS OF PEPTIDES | NOVO NORDISK A/S (DK) | 2006-02-23 | — | — | WO | disclosed |
| WO-2006013202-A2 | CONJUGATION OF FVII | NOVO NORDISK HEALTH CARE AG (DK) | 2006-02-09 | — | — | WO | disclosed |
| US-20060018831-A1 | TF binding agent and use thereof | NOVO NORDISK A/S (DK) | 2006-01-26 | — | — | US | disclosed |
| WO-2006005667-A2 | POLYPEPTIDE PROTRACTING TAGS COMPRISING A TETRAZOLE MOIETY | NOVO NORDISK A/S (DK) | 2006-01-19 | — | — | WO | disclosed |
| WO-2006003179-A2 | ANTIBODIES BINDING TO RECEPTORS KIR2DL1, -2, 3 BUT NOT KIR2DS4 AND THEIR THERAPEUTIC USE | NOVO NORDISK A/S (DK) | 2006-01-12 | — | — | WO | disclosed |
| WO-2006000567-A2 | USE OF GLP-1 RECEPTOR AGONISTS AND / OR DPP-IV INHIBITORS IN COMBINATION WITH PROTON PUMP INHIBITORS AND PPAR AGONISTS FOR THE PREPARATION OF A MEDICAMENT FOR THE TREATMENT OF DIABETES TYPE I I AND IMPAIRED PANCREATIC BETA-CELL FUNCTION | NOVO NORDISK A/S (DK) | 2006-01-05 | — | — | WO | disclosed |
| WO-2005117948-A1 | METHOD OF STABILIZING PROTEINS | ARES TRADING S.A. (CH) | 2005-12-15 | — | — | WO | disclosed |
| WO-2005118630-A2 | PEPTIDES FOR THE TREATMENT OF DIABETES | NOVO NORDISK A/S (DK) | 2005-12-15 | — | — | WO | disclosed |
| EP-0922454-B1 | Arginine antagonists for inhibition of systemic hypotension associated with nitric oxide production or endothelial derived relaxing factor | UNIV TEXAS (US) | 2005-11-16 | — | — | EP | disclosed |
| WO-2005100571-A1 | OSTEOGENIC GROWTH PEPTIDE FUSION PROTEINS | NOVO NORDISK A/S (DK) | 2005-10-27 | — | — | WO | disclosed |
| EP-1587549-A2 | RADIOLABELLED TISSUE FACTOR BINDING AGENT AND THE USE THEREOF | NOVO NORDISK A/S (DK) | 2005-10-26 | — | — | EP | disclosed |
| WO-2005085862-A1 | SCREEN FOR THE IDENTIFICATION OF AGENTS USEFUL IN THE TREATMENT OF CANCERS | UNIVERSITY COLLEGE LONDON (GB) | 2005-09-15 | — | — | WO | disclosed |
| US-20050181978-A1 | Therapeutic use of factor XI | ROJKJAER RASMUS (DK) | 2005-08-18 | — | — | US | disclosed |
| EP-1561471-A1 | CELL GROWTH REGULATOR | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2005-08-10 | — | — | EP | disclosed |
| US-20050155115-A1 | Use of Nitric Oxide Modulators in Agrobacterium-mediated Plant Transformation | MONSANTO TECHNOLOGY LLC (US) | 2005-07-14 | — | — | US | disclosed |
| WO-2005058954-A1 | NOVEL GLP-1 COMPOUNDS | NOVO NORDISK A/S (DK) | 2005-06-30 | — | — | WO | disclosed |
| WO-2005058958-A2 | NOVEL GLP-1 ANALOGUES LINKED TO ALBUMIN-LIKE AGENTS | NOVO NORDISK A/S (DK) | 2005-06-30 | — | — | WO | disclosed |
| WO-2005049070-A1 | THERAPEUTIC USE OF FACTOR XI | NOVO NORDISK HEALTH CARE AG (CH) | 2005-06-02 | — | — | WO | disclosed |
| US-6894069-B2 | Method for treating perinatal asphyxia in a human or animal neonate | UNIVERSITAIR MEDISCH CENTRUM (NL) | 2005-05-17 | — | — | US | disclosed |
| WO-2005042016-A2 | STABILISED COMPOSITIONS | CHIRON CORPORATION (US) | 2005-05-12 | — | — | WO | disclosed |
| WO-2005037306-A1 | COMBINATION THERAPY | NOVO NORDISK A/S (DK) | 2005-04-28 | — | — | WO | disclosed |
| WO-2005035565-A1 | IL-21 DERIVATIVES | NOVO NORDISK A/S (DK) | 2005-04-21 | — | — | WO | disclosed |
| WO-2005028516-A2 | ALBUMIN-BINDING DERIVATIVES OF THERAPEUTIC PEPTIDES | NOVO NORDISK A/S (DK) | 2005-03-31 | — | — | WO | disclosed |
| WO-2005027978-A2 | ALBUMIN-BINDING DERIVATIVES OF THERAPEUTIC PEPTIDES | NOVO NORDISK A/S (DK) | 2005-03-31 | — | — | WO | disclosed |
| WO-2005014028-A1 | INTERLEUKIN-20 FOR TREATING AND DIAGNOSING CONDITIONS ASSOCIATED WITH NEOVASCULARISATION | NOVO NORDISK A/S (DK) | 2005-02-17 | — | — | WO | disclosed |
| WO-2005014049-A2 | SYNTHESIS AND APPLICATION OF NEW STRUCTURAL WELL DEFINED BRANCHED POLYMERS AS CONJUGATING AGENTS FOR PEPTIDES | NOVO NORDISK A/S (DK) | 2005-02-17 | — | — | WO | disclosed |
| US-20050009915-A1 | Method for preventing and/or treating perinatal asphyxia in a human or animal neonate | NEUROPHYXIA B.V. (NL) | 2005-01-13 | — | — | US | disclosed |
| US-20040266743-A1 | Combination of an aldosterone receptor antagonist and a renin inhibitor | PHARMACIA CORPORATION | 2004-12-30 | — | — | US | disclosed |
| EP-1485132-A2 | COMBINATION OF AN ALDOSTERONE RECEPTOR ANTAGONIST AND A FIBRIC ACID DERIVATIVE | Pharmacia Corporation (US) | 2004-12-15 | — | — | EP | disclosed |
| EP-1485104-A1 | COMBINATION OF AN ALDOSTERONE RECEPTOR ANTAGONIST AND NICOTINIC ACID OR A NICOTINIC ACID DERIVATIVE | Pharmacia Corporation (US) | 2004-12-15 | — | — | EP | disclosed |
| EP-1485105-A1 | COMBINATION OF AN ALDOSTERONE RECEPTOR ANTAGONIST AND A BILE ACID SEQUESTERING AGENT | Pharmacia Corporation (US) | 2004-12-15 | — | — | EP | disclosed |
| WO-2004100871-A2 | COMBINATION OF AN ALDOSTERONE RECEPTOR ANTAGONIST AND A RENIN INHIBITOR | PHARMACIA CORPORATION (US) | 2004-11-25 | — | — | WO | disclosed |
| US-20040192584-A1 | Combination of an aldosterone receptor antagonist and a neutral endopeptidase inhibitor | PHARMACIA CORPORATION | 2004-09-30 | — | — | US | disclosed |
| WO-2004082636-A2 | COMBINATION OF AN ALDOSTERONE RECEPTOR ANTAGONIST AND A NEUTRAL ENDOPEPTIDASE INHIBITOR | PHARMACIA CORPORATION (US) | 2004-09-30 | — | — | WO | disclosed |
| WO-2004064870-A2 | RADIOLABELLED TISSUE FACTOR BINDING AGENT AND THE USE THEREOF | NOVO NORDISK A/S (DK) | 2004-08-05 | — | — | WO | disclosed |
| US-20040102424-A1 | Methods for the treatment or prophylaxis of aldosterone-mediated pathogenic effects in a subject using an epoxy-steroidal aldosterone antagonist | G.D. SEARLE & CO. | 2004-05-27 | — | — | US | disclosed |
| US-20040067918-A1 | Combination of an aldosterone receptor antagonist and nicotinic acid or a nicotinic acid derivative | PHARMACIA CORPORATION | 2004-04-08 | — | — | US | disclosed |
| US-6713079-B2 | CONTACTING THE SITE OF WOUND WITH A MATRIX COMPRISING GELATIN AND A NITRIC OXIDE SCAVANGER TO INCREASE BLOOD CIRULATION; NITRIC OXIDE SCAVANGER ARE SELECTED FROM L-ARGANINE ANALOG, DEXTRAN, HEPARIN, CYSTEINE AND CYSTINE | ENCELLE, INC. | 2004-03-30 | — | — | US | disclosed |
| US-20040002530-A1 | Composition for the prevention and/or treatment in newborn babies of the effects of complications during childbirth | NEUROPHYXIA B.V. (NL) | 2004-01-01 | — | — | US | disclosed |
| US-20030219401-A1 | Combination of an aldosterone receptor antagonist and a bile acid sequestering agent | THE RELIABLE AUTOMATIC SPRINKLER CO. INC. | 2003-11-27 | — | — | US | disclosed |
| WO-2003097085-A1 | DDAH MODULATORS IN THE TREATMENT OF PAIN | UNIVERSITY COLLEGE LONDON (GB) | 2003-11-27 | — | — | WO | disclosed |
| WO-2003097084-A1 | DDAH MODULATORS IN THE TREATMENT OF PAIN | UNIVERSITY COLLEGE LONDON (GB) | 2003-11-27 | — | — | WO | disclosed |
| US-20030203884-A1 | Methods for the treatment or prophylaxis of aldosterone-mediated pathogenic effects in a subject using an epoxy-steroidal aldosterone antagonist | PHARMACIA CORPORATION (US) | 2003-10-30 | — | — | US | disclosed |
| US-20030191100-A1 | Methods for the treatment or prophylaxis of aldosterone-mediated pathogenic effects in a subject | PHARMACIA CORPORATION, CORPORATE PATENT DEPARTMENT | 2003-10-09 | — | — | US | disclosed |
| WO-2003080068-A1 | COMBINATION OF AN ALDOSTERONE RECEPTOR ANTAGONIST AND NICOTINIC ACID OR A NICOTINIC ACID DERIVATIVE | PHARMACIA CORPORATION (US) | 2003-10-02 | — | — | WO | disclosed |
| WO-2003080118-A2 | COMBINATION OF AN ALDOSTERONE RECEPTOR ANTAGONIST AND A FIBRIC ACID DERIVATIVE | PHARMACIA CORPORATION (US) | 2003-10-02 | — | — | WO | disclosed |
| WO-2003080069-A1 | COMBINATION OF AN ALDOSTERONE RECEPTOR ANTAGONIST AND A BILE ACID SEQUESTERING AGENT | PHARMACIA CORPORATION (US) | 2003-10-02 | — | — | WO | disclosed |
| US-20030180253-A1 | Stabilized liquid polypeptide-containing pharmaceutical compositions | CHIRON CORPORATION | 2003-09-25 | — | — | US | disclosed |
| EP-0865288-B1 | BIOARTIFICIAL DEVICES AND CELLULAR MATRICES THEREFOR | ENCELLE INC (US) | 2003-08-20 | — | — | EP | disclosed |
| EP-1321516-A2 | Hydrogel matrix for cellular tissue storage | ENCELLE, INC. (US) | 2003-06-25 | — | — | EP | disclosed |
| EP-1095007-B1 | WATER-SOLUBLE ZINC PYRUVATES OR THEIR HYDRATES, METHOD FOR THE PRODUCTION THEREOF AND THEIR USE | FINZELBERG GMBH & CO KG (DE) | 2003-06-04 | — | — | EP | disclosed |
| US-20030096798-A1 | Methods for the treatment or prophylaxis of aldosterone-mediated pathogenic effects in a subject using an epoxy-steroidal aldosterone antagonist | WILLIAMS GORDON H (US) | 2003-05-22 | — | — | US | disclosed |
| EP-1289507-A1 | USE OF AN ALDOSTERONE ANTAGONIST FOR THE TREATMENT OR PROHPYLAXIS OF ALDOSTERONE-MEDIATED PATHOGENIC EFFECTS | Pharmacia Corporation (US) | 2003-03-12 | — | — | EP | disclosed |
| US-6525102-B1 | Increasing storage stability of interleukin-2 by incorporating free base form arginine and succinic acid | CHIRON CORPORATION | 2003-02-25 | — | — | US | disclosed |
| EP-1280526-A1 | COMPOSITION FOR THE PREVENTION AND/OR TREATMENT, IN NEWBORN BABIES, OF THE EFFECTS OF COMPLICATIONS DURING CHILDBIRTH | Universitair Medisch Centrum Utrecht (NL) | 2003-02-05 | — | — | EP | disclosed |
| EP-1220682-A1 | STABILIZED LIQUID POLYPEPTIDE-CONTAINING PHARMACEUTICAL COMPOSITIONS | CHIRON CORPORATION (US) | 2002-07-10 | — | — | EP | disclosed |
| WO-2002043717-A2 | TREATMENT OF VARICOSE VEINS | UNIVERSITY COLLEGE LONDON (GB) | 2002-06-06 | — | — | WO | disclosed |
| US-20020061862-A1 | Inducible nitric oxide synthase for treatment of disease | UNIVERSITY OF PITTSBURGH OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION | 2002-05-23 | — | — | US | disclosed |
| EP-1203098-A2 | INDUCIBLE SCREEN FOR DRUG DISCOVERY | University College London (GB) | 2002-05-08 | — | — | EP | disclosed |
| WO-2002020834-A2 | METHOD FOR THE IDENTIFICATION OF GENES THAT ARE INVOLVED IN THE MODULATION OF A POPTOSIS IN CELLS | EIRX THERAPEUTICS LIMITED (IE) | 2002-03-14 | — | — | WO | disclosed |
| WO-2002002812-A2 | METHOD FOR DETERMINING THE SUSCEPTIBILITY TO STOKE BY ANALYSING THE INS GENE | UNIVERSITY COLLEGE LONDON (GB) | 2002-01-10 | — | — | WO | disclosed |
| US-20010056068-A1 | METHOD OF TREATMENT AND PREVENTION OF NITRIC OXIDE DEFICIENCY-RELATED DISORDERS WITH CITRULLINE AND CITRULLINE DERIVATIVES | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM | 2001-12-27 | — | — | US | disclosed |
| WO-2001095892-A1 | USE OF AN ALDOSTERONE ANTAGONIST FOR THE TREATMENT OR PROHPYLAXIS OF ALDOSTERONE-MEDIATED PATHOGENIC EFFECTS | PHARMACIA CORPORATION (US) | 2001-12-20 | — | — | WO | disclosed |
| WO-2001095893-A1 | USE OF AN EPOXY-STEROIDAL ALDOSTERONE ANTAGONIST FOR THE TREATMENT OR PROPHYLAXIS OF ALDOSTERONE-MEDIATED PATHOGENIC EFFECTS | PHARMACIA CORPORATION (US) | 2001-12-20 | — | — | WO | disclosed |
| US-6307080-B1 | TREATING DIABETES OR TREATING COLDS INHIBITING VIRUS, ENHANCING CYTROPROTECTION, INDUCING MICOBICIDAL ACTIVITY AND ABSORBING RADICALS; ZINC DEFICIENCY | SKW TROSTBERG AKTIENGESELLSCHAFT (DE) | 2001-10-23 | — | — | US | disclosed |
| WO-2001074351-A1 | COMPOSITION FOR THE PREVENTION AND/OR TREATMENT, IN NEWBORN BABIES, OF THE EFFECTS OF COMPLICATIONS DURING CHILDBIRTH | UNIVERSITAIR MEDISCH CENTRUM (NL) | 2001-10-11 | — | — | WO | disclosed |
| US-6274557-B1 | DIPEPTIDE CONTAINING NITROARGININE OR ESTER OR AMIDE DERIVATIVE | NORTHWESTERN UNIVERSITY | 2001-08-14 | — | — | US | disclosed |
| US-20010010826-A1 | Methods for increasing vascularization and promoting wound healing | ENCELLE, INC. | 2001-08-02 | — | — | US | disclosed |
| US-6261587-B1 | CONTACTING WITH MATRIX CONTAINING GELATIN AND NITRIC ACID INHIBITOR | ENCELLE, INC. | 2001-07-17 | — | — | US | disclosed |
| EP-1095007-A1 | WATER-SOLUBLE ZINC PYRUVATES OR THEIR HYDRATES, METHOD FOR THE PRODUCTION THEREOF AND THEIR USE | SKW Trostberg Aktiengesellschaft (DE) | 2001-05-02 | — | — | EP | disclosed |
| EP-1094849-A1 | METHODS FOR INCREASING VASCULARIZATION AND PROMOTING WOUND HEALING | Encelle, Inc. (US) | 2001-05-02 | — | — | EP | disclosed |
| WO-2001024814-A1 | STABILIZED LIQUID POLYPEPTIDE-CONTAINING PHARMACEUTICAL COMPOSITIONS | CHIRON CORPORATION (US) | 2001-04-12 | — | — | WO | disclosed |
| WO-2001009375-A2 | INDUCIBLE SCREEN FOR DRUG DISCOVERY | UNIVERSITY COLLEGE LONDON (GB) | 2001-02-08 | — | — | WO | disclosed |
| EP-1046392-A2 | Cosmetic and dermatologic compositions for improving the skin barrier function | Beiersdorf AG (DE) | 2000-10-25 | — | — | EP | disclosed |
| WO-2000002841-A1 | WATER-SOLUBLE ZINC PYRUVATES OR THEIR HYDRATES, METHOD FOR THE PRODUCTION THEREOF AND THEIR USE | SKW TROSTBERG AKTIENGESELLSCHAFT (DE) | 2000-01-20 | — | — | WO | disclosed |
| WO-2000002596-A1 | METHODS FOR INCREASING VASCULARIZATION AND PROMOTING WOUND HEALING | ENCELLE, INC. (US) | 2000-01-20 | — | — | WO | disclosed |
| EP-0938258-A4 | EMULSIONS OF PERFLUORO COMPOUNDS AS SOLVENTS FOR NITRIC OXIDE (NO) | UNIV TEXAS (US) | 2000-01-19 | — | — | EP | disclosed |
| EP-0969790-A2 | COMPOSITIONS FOR TREATING ACNE ROSACEA | Beiersdorf Aktiengesellschaft (DE) | 2000-01-12 | — | — | EP | disclosed |
| EP-0769903-A4 | INDUCIBLE NITRIC OXIDE SYNTHASE GENE FOR TREATMENT OF DISEASE | UNIV PITTSBURGH (US) | 1999-10-27 | — | — | EP | disclosed |
| EP-0938258-A1 | EMULSIONS OF PERFLUORO COMPOUNDS AS SOLVENTS FOR NITRIC OXIDE (NO) | THE BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 1999-09-01 | — | — | EP | disclosed |
| EP-0922454-A2 | Arginine antagonists for inhibition of systemic hypotension associated with nitric oxide production or endothelial derived relaxing factor | Board of Regents, The University of Texas System (US) | 1999-06-16 | — | — | EP | disclosed |
| EP-0669824-B1 | USE OF CARDIOTONIC DRUGS AND INHIBITORS OF NITRIC OXIDE SYNTHESIS TO ALLEVIATE PATHOLOGIC HYPOTENSION | UNIV TEXAS (US) | 1999-04-07 | — | — | EP | disclosed |
| EP-0597831-B1 | ARGININE ANTAGONISTS FOR INHIBITION OF SYSTEMIC HYPOTENSION ASSOCIATED WITH NITRIC OXIDE PRODUCTION OR ENDOTHELIAL DERIVED RELAXING FACTOR | UNIV TEXAS (US) | 1999-01-20 | — | — | EP | disclosed |
| EP-0649303-B1 | SUBSTITUTED ARGININES AND SUBSTITUTED HOMOARGININES AND USE THEREOF | CORNELL RES FOUNDATION INC (US) | 1998-11-25 | — | — | EP | disclosed |
| WO-1998048826-A1 | INHIBITION OF NITRIC OXIDE SYNTHASE BY AMINO ACIDS AND DIPEPTIDES | NORTHWESTERN UNIVERSITY (US) | 1998-11-05 | — | — | WO | disclosed |
| US-5830492-A | MATRIX CONTAINING A HORMONE ENCAPSULATED WITH POLYMER | ENCELLE, INC. | 1998-11-03 | — | — | US | disclosed |
| EP-0865288-A2 | BIOARTIFICIAL DEVICES AND CELLULAR MATRICES THEREFOR | Encelle, Inc. (US) | 1998-09-23 | — | — | EP | disclosed |
| WO-1998036730-A2 | COMPOSITIONS FOR TREATING ACNE ROSACEA | BEIERSDORF AG (DE) | 1998-08-27 | — | — | WO | disclosed |
| WO-1997038579-A1 | EMULSIONS OF PERFLUORO COMPOUNDS AS SOLVENTS FOR NITRIC OXIDE (NO) | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 1997-10-23 | — | — | WO | disclosed |
| WO-1997020569-A2 | BIOARTIFICIAL DEVICES AND CELLULAR MATRICES THEREFOR | ENCELLE, INC. (US) | 1997-06-12 | — | — | WO | disclosed |
| EP-0769903-A1 | INDUCIBLE NITRIC OXIDE SYNTHASE GENE FOR TREATMENT OF DISEASE | UNIVERSITY OF PITTSBURGH OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 1997-05-02 | — | — | EP | disclosed |
| EP-0768875-A1 | NITRIC OXIDE SYNTHASE INHIBITORS FOR INHIBITING THE PRODUCTION OF AIRWAY MUCUS | THE WELLCOME FOUNDATION LIMITED (GB) | 1997-04-23 | — | — | EP | disclosed |
| EP-0705098-A1 | METHODS FOR IMPROVING THERAPEUTIC EFFECTIVENESS OF AGENTS FOR THE TREATMENT OF SOLID TUMORS AND OTHER DISORDERS | APEX BIOSCIENCE, INC. (US) | 1996-04-10 | — | — | EP | disclosed |
| WO-1996002245-A1 | NITRIC OXIDE SYNTHASE INHIBITORS FOR INHIBITING THE PRODUCTION OF AIRWAY MUCUS | THE WELLCOME FOUNDATION LIMITED (GB) | 1996-02-01 | — | — | WO | disclosed |
| WO-1996000006-A1 | INDUCIBLE NITRIC OXIDE SYNTHASE GENE FOR TREATMENT OF DISEASE | UNIVERSITY OF PITTSBURGH OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 1996-01-04 | — | — | WO | disclosed |
| EP-0649303-A4 | SUBSTITUTED ARGININES AND SUBSTITUTED HOMOARGININES AND USE THEREOF. | CORNELL RES FOUNDATION INC (US) | 1995-07-05 | — | — | EP | disclosed |
| WO-1995015753-A1 | OVULATION CONTROL BY REGULATING NITRIC OXIDE LEVELS | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 1995-06-15 | — | — | WO | disclosed |
| EP-0649303-A1 | SUBSTITUTED ARGININES AND SUBSTITUTED HOMOARGININES AND USE THEREOF | CORNELL RESEARCH FOUNDATION, INC. (US) | 1995-04-26 | — | — | EP | disclosed |
| WO-1994027585-A1 | METHODS FOR IMPROVING THERAPEUTIC EFFECTIVENESS OF AGENTS FOR THE TREATMENT OF SOLID TUMORS AND OTHER DISORDERS | APEX BIOSCIENCE, INC. (US) | 1994-12-08 | — | — | WO | disclosed |
| WO-1993024126-A1 | SUBSTITUTED ARGININES AND SUBSTITUTED HOMOARGININES AND USE THEREOF | CORNELL RESEARCH FOUNDATION, INC. (US) | 1993-12-09 | — | — | WO | disclosed |
| WO-1993024126-A1 | SUBSTITUTED ARGININES AND SUBSTITUTED HOMOARGININES AND USE THEREOF | CORNELL RESEARCH FOUNDATION, INC. (US) | 1993-12-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (50 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10105442-B2 | Treatment of diabetes type 1 using GLP-1 and anti-IL-21 | GLP1R, IAPP, IL1A | FOLH1 442/4885C3AR1 1614/4885NOD1 95/4885 |
| US-20200102568-A1 | Growth Hormones with Prolonged In-Vivo Efficacy | SHBG, GHRHR, GHITM | FOLH1 469/4885C3AR1 1771/4885NOD1 4722/4885 |
| US-10092580-B2 | Controlled-release otic structure modulating and innate immune system modulating compositions and methods for the treatment of otic disorders | OTC, TLR3, STING1 | FOLH1 448/4885C3AR1 98/4885NOD1 117/4885 |
| US-20130143798-A1 | NOVEL GLUCAGON ANALOGUES | GLP1R, GCG, IAPP | FOLH1 251/4885C3AR1 3069/4885NOD1 1083/4885 |
| US-20080305986-A1 | Multimers of Peptides | IAPP, NGLY1, VIP | FOLH1 211/4885C3AR1 767/4885NOD1 341/4885 |
| US-20060018831-A1 | TF binding agent and use thereof | TFPI, F3, TFPI2 | FOLH1 421/4885C3AR1 163/4885NOD1 3260/4885 |
| US-20040266743-A1 | Combination of an aldosterone receptor antagonist and a renin inhibitor | REN, AGTR1, AGTR2 | FOLH1 1962/4885C3AR1 644/4885NOD1 2136/4885 |
| US-20140243425-A1 | CONTROLLED RELEASE COMPOSITIONS FOR MODULATING FREE-RADICAL INDUCED DAMAGE AND METHODS OF USE THEREOF | OTC, ARG2, COX6A1 | FOLH1 372/4885C3AR1 871/4885NOD1 2206/4885 |
| US-20100022661-A1 | CONTROLLED RELEASE COMPOSITIONS FOR MODULATING FREE-RADICAL INDUCED DAMAGE AND METHODS OF USE THEREOF | OTC, ARG2, COX6A1 | FOLH1 372/4885C3AR1 871/4885NOD1 2206/4885 |
| US-20150182594-A1 | NOVEL GLUCAGON ANALOGUES | GLP1R, GCG, GCGR | FOLH1 352/4885C3AR1 2561/4885NOD1 1939/4885 |
| US-20170043014-A1 | TREATMENT OF DIABETES TYPE 1 USING GLP-1 AND ANTI-IL-21 | GLP1R, IAPP, IL1A | FOLH1 442/4885C3AR1 1614/4885NOD1 95/4885 |
| US-20080207507-A1 | Extended Glp-1 Compounds | GLP1R, GIPR, IAPP | FOLH1 274/4885C3AR1 4779/4885NOD1 933/4885 |
| US-20150025003-A1 | GLUCAGON-LIKE PEPTIDE-1 DERIVATIVES AND THEIR PHARMACEUTICAL USE | GLP1R, GIPR, GCGR | FOLH1 411/4885C3AR1 1517/4885NOD1 323/4885 |
| US-20170190757-A1 | Novel Glucagon Analogues | GLP1R, GIPR, IAPP | FOLH1 303/4885C3AR1 3035/4885NOD1 1856/4885 |
| US-20180000950-A1 | TRIGLYCERIDE OTIC FORMULATIONS AND USES THEREOF | CETP, LIPA, APOB | FOLH1 1263/4885C3AR1 3944/4885NOD1 3675/4885 |
| US-20100056428-A1 | MODIFIED PROTEINS | PTMS, CD2BP2, SIGLEC7 | FOLH1 724/4885C3AR1 781/4885NOD1 2967/4885 |
| US-20090252720-A1 | Prolonged FIX Analogues and Derivatives | FGB, F2, F8 | FOLH1 319/4885C3AR1 85/4885NOD1 3968/4885 |
| US-20130040884-A1 | ALBUMIN-BINDING CONJUGATES COMPRISING FATTY-ACID AND PEG | FABP1, FABP2, FABP4 | FOLH1 340/4885C3AR1 1600/4885NOD1 3894/4885 |
| US-20200223889-A1 | Bicyclic Compounds Capable of Binding to Melanocortin 4 Receptor | MC4R, MC5R, MC3R | FOLH1 893/4885C3AR1 430/4885NOD1 2537/4885 |
| US-20140329750-A1 | Growth Hormones with Prolonged In-Vivo Efficacy | GHRHR, GHITM, SHBG | FOLH1 214/4885C3AR1 1271/4885NOD1 4234/4885 |
| US-20140011732-A1 | Peptides Derivatized with A-B-C-D- and their Therapeutical Use | GLP1R, IAPP, GIPR | FOLH1 629/4885C3AR1 426/4885NOD1 266/4885 |
| US-20100184641-A1 | Novel Plasma Protein Affinity Tags | CD2BP2, HDLBP, SERPINA6 | FOLH1 956/4885C3AR1 1624/4885NOD1 3562/4885 |
| US-20090005312-A1 | NOVEL GLP-1 ANALOGUES LINKED TO ALBUMIN-LIKE AGENTS | GLP1R, GIPR, IAPP | FOLH1 230/4885C3AR1 2508/4885NOD1 502/4885 |
| US-20070105750-A1 | Novel plasma protein affinity tags | CD2BP2, HDLBP, SERPINA6 | FOLH1 956/4885C3AR1 1624/4885NOD1 3562/4885 |
| US-20060182714-A1 | Synthesis and application of new structural well defined branched polymers as conjugating agents for peptides | VIP, PTMS, PDGFA | FOLH1 1062/4885C3AR1 913/4885NOD1 3154/4885 |
| US-20210138069-A1 | TRIGLYCERIDE OTIC FORMULATIONS AND USES THEREOF | CETP, LIPA, APOB | FOLH1 1202/4885C3AR1 4096/4885NOD1 3797/4885 |
| US-20190300570-A1 | SITE-SPECIFIC CHEMOENZYMATIC PROTEIN MODIFICATIONS | PTMS, TGM3, TGM1 | FOLH1 28/4885C3AR1 1791/4885NOD1 3613/4885 |
| US-20130203672-A1 | Novel Glucagon Like Peptide Analogs, Composition, and Method of Use | IAPP, GLP1R, GIPR | FOLH1 536/4885C3AR1 2200/4885NOD1 631/4885 |
| US-20090318353-A1 | Acylated Exendin-4 Compounds | GLP1R, VIP, IAPP | FOLH1 1031/4885C3AR1 2308/4885NOD1 2160/4885 |
| US-20100222269-A1 | IMPROVED DERIVATIVES OF AMYLIN | IAPP, GLP1R, ALB | FOLH1 1735/4885C3AR1 117/4885NOD1 281/4885 |
| US-20100016238-A1 | Peptides for Use in the Treatment of Obesity | MC4R, GIPR, MC3R | FOLH1 357/4885C3AR1 465/4885NOD1 4131/4885 |
| US-11352406-B2 | Insulin derivatives and the medical uses hereof | IAPP, INSR, IRS1 | FOLH1 2034/4885C3AR1 3156/4885NOD1 2706/4885 |
| US-20120172303-A1 | Growth Hormones with Prolonged In-Vivo Efficacy | GHRHR, GHITM, SHBG | FOLH1 214/4885C3AR1 1271/4885NOD1 4234/4885 |
| US-20090042781-A1 | Methods for Treating Diabetes | GLP1R, DPP4, GIPR | FOLH1 787/4885C3AR1 4800/4885NOD1 2348/4885 |
| US-20070292391-A1 | Stabilized Interferon Liquid Formulations | IFNG, IFNAR1, IL2 | FOLH1 1429/4885C3AR1 3577/4885NOD1 3135/4885 |
| US-20030096798-A1 | Methods for the treatment or prophylaxis of aldosterone-mediated pathogenic effects in a subject using an epoxy-steroidal aldosterone antagonist | NR3C2, CYP21A2, REN | FOLH1 1876/4885C3AR1 945/4885NOD1 3825/4885 |
| US-20130281363-A1 | POLYPEPTIDES | IAPP, GLP1R, AMY2A | FOLH1 461/4885C3AR1 305/4885NOD1 2327/4885 |
| US-20250326814-A1 | MODIFIED OXYNTOMODULIN AND METHODS OF USE THEREOF | OGFRL1, OXGR1, THOP1 | FOLH1 1679/4885C3AR1 1151/4885NOD1 628/4885 |
| US-20160120997-A1 | Modified Glycoproteins Having Circulating Half-Lives | SIGLEC7, FUT4, SELPLG | FOLH1 195/4885C3AR1 271/4885NOD1 2575/4885 |
| US-20080306008-A1 | Peptides for Use in the Treatment of Obesity | MC4R, GIPR, MC3R | FOLH1 357/4885C3AR1 465/4885NOD1 4131/4885 |
| US-20120021973-A1 | Peptides for Treatment of Obesity | MC4R, GIPR, MC3R | FOLH1 449/4885C3AR1 388/4885NOD1 3998/4885 |
| US-20140031278-A1 | Novel Glucagon Analogues | GLP1R, GCG, IAPP | FOLH1 247/4885C3AR1 2817/4885NOD1 1052/4885 |
| US-12077561-B2 | CNP compounds | NPPA, NPR1, NPR3 | FOLH1 562/4885C3AR1 172/4885NOD1 622/4885 |
| US-20120309944-A1 | Growth Hormones With Prolonged In-Vivo Efficacy | GHRHR, SHBG, GHSR | FOLH1 343/4885C3AR1 1465/4885NOD1 4656/4885 |
| US-20090264366-A1 | Transglutaminase Mediated Conjugation of Peptides | TGM2, TGM3, TGM1 | FOLH1 18/4885C3AR1 2924/4885NOD1 3986/4885 |
| US-20090062192-A1 | Dimeric Peptide Agonists of the Glp-1 Receptor | GLP1R, GIPR, IAPP | FOLH1 183/4885C3AR1 3946/4885NOD1 178/4885 |
| US-20100016237-A1 | Novel Peptides for Use in the Treatment of Obesity | MC4R, MC3R, GIPR | FOLH1 343/4885C3AR1 325/4885NOD1 3861/4885 |
| US-20180221501-A1 | Growth Hormones with Prolonged In-Vivo Efficacy | GHRHR, GHITM, SHBG | FOLH1 214/4885C3AR1 1271/4885NOD1 4234/4885 |
| US-20130053310-A1 | NOVEL GLUCAGON ANALOGUES | GLP1R, IAPP, GCG | FOLH1 448/4885C3AR1 2504/4885NOD1 1757/4885 |
| US-20130005646-A1 | POLYPEPTIDES | IAPP, GLP1R, GIPR | FOLH1 98/4885C3AR1 661/4885NOD1 3819/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.